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ABSTRACT 
 
Bone metastasis of a predominantly osteoblastic (sclerotic) nature is the outcome for 
the vast majority of patients with castration-resistant prostate cancer (CRPC). 
Pathologically, osteoblastic tumors are characterized by excessive bone formation 
resulting in decreased quality of life due to severe pain, fractures, nerve compression, 
and  a  suppressed  immune  system.  Despite  the  success  of  novel  therapeutic 
approaches, castration-resistant tumors remain the primary unsolved obstacle for 
patient survival. Therefore, an improved understanding of the molecular mechanisms 
behind the osteoblastic growth of CRPC is important in the search for novel 
therapeutic strategies. The aim of this thesis was to investigate the specific role of 
osteoblasts in the growth of prostate cancer in bone. By establishing and 
characterizing a novel model of sclerotic CRPC, it was demonstrated that both 
osteoblasts and prostate cancer cells are potential mediators of bone formation. It was 
further demonstrated that osteoblasts promote the osteogenic and metastatic 
progression of CRPC cells and potentiate the cross talk between CRPC and bone 
cells. Moreover, it was shown that osteoblasts induce and alter steroidogenesis in the 
CRPC cells by increasing the expression of steroidogenic enzymes in a similar 
manner to what has previously been described in bone metastases from patients. 
Further studies reveled that Runt-related transcription factor 2 (RUNX2) – which is 
under the control of osteoblasts – is a putative regulator of de novo steroid synthesis 
in osteogenic CRPC cells, and this mimics a mechanism of steroid synthesis 
previously   only   described   in   osteoblasts.   Finally,   a   preclinical   study   with 
tasquinimod showed that this drug efficiently impaired the establishment of bone 
metastases in mice by interfering with the osteoblastic pre-metastatic niche and 
osteoblastic activity, thus emphasizing the role of osteoblasts in the early phases of 
the metastatic process. In summary, the studies performed in this thesis have 
characterized the role of osteoblasts in castration-resistant growth of prostate cancer 
in bone and suggest that osteoblasts could be an attractive target for the development 
of novel therapeutic approaches. A better understanding of the osteoblast–tumor cell 
interaction might facilitate the design of treatment strategies targeting the osteoblasts 
as a way to inhibit the metastatic process and thus bypass the castration resistance of 
CRPC bone metastases. 
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POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
Prostatacancer är idag den cancerform som både drabbar flest och står för den 
högsta cancerrelaterade dödligheten bland svenska män. Varje år 
diagnostiseras cirka 9200 män och ca 2300 av dessa kommer att dö av 
sjukdomen. Vid tidig upptäckt är prognosen god, då cancern är lokaliserad i 
prostatan, men vid en spridd (metastaserad) sjukdom finns ingen botande 
behandling. I dessa fall behandlas cancern med kastrationsbehandling, med 
syftet att blockera produktionen av manligt könshormon som cancertumören 
är beroende av för sin tillväxt. För majoriteten av patienter är 
behandlingseffekten initialt god och har en hämmande effekt på tumören men 
effekten är tyvärr inte bestående. Inom loppet av två år övergår ca 80 % av 
fallen till en mer aggressiv form med spridning till andra delar av kroppen 
utanför prostatan. Denna form kallas kastrationsresistent prostatacancer 
(CRPC)  och  innebär  att  cancertumören  kan  växa  trots  sänkta  nivåer  av 
manligt könshormon. Det finns flera föreslagna mekanismer till hur tumören 
anpassar sig till fortsatt tillväxa utan könshormonet. En av förklaringarna är 
att tumörcellerna själva börjar producera de könshormoner de behöver för sin 
tillväxt. CRPC uppkommer huvudsakligen som metastaser i skelettet och 
bildar, till skillnad från andra cancerformer som ofta bryter ner ben, en ökad 
benmassa. Mekanismerna bakom tumörtillväxten i skelettet och vilken 
betydelse cellerna i benet har i denna process är till stor del okänt. För 
patienter med tumörer i skelettet är överlevnaden kort och ofta förenad med 
svåra smärtor på grund av tumörens växtsätt. På grund av svårigheter att få 
tillgång till kliniskt material från denna patientgrupp och bristen av modeller 
som  liknar  den  kliniska  bilden  är  utvecklandet  av  nya  experimentella 
modeller av största vikt för att kunna studera bakomliggande mekanismer för 
denna idag obotliga sjukdom. Syftet med denna avhandling var att studera 
samspelet mellan osteoblaster, de benbyggande cellerna i skelettet, och 
tumörceller i CRPC i ben. Målet var att öka förståelsen för hur osteoblastiska 
benmetastaser bildas och växer och därmed hitta nya sätt att behandla dessa 
tumörer. 
 
I denna avhandling karaktäriserades en ny modell, LNCaP-19, för att 
möjliggöra studier av tumörtillväxten av CRPC i ben. I denna modell påvisar 
vi hur osteoblaster driver på aggressiva egenskaper i tumörcellerna samt 
stimulerar dessa att förvärva benlika egenskaper som gör att de bättre smälter 
in i benmiljön. Vidare visar vi att samspelet mellan osteoblaster och 
tumörcellernas förmåga att själva bilda de könshormoner som 
kastrationsbehandlingen blockerar. Osteoblasterna påverkar tumörcellernas 
produktion av könshormon på ett sätt som stämmer väl överrens med det man 
sett tidigare i benmetastaser från patienter. Avhandlingen visar även att ett 
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ökat uttryck av RUNX2, ett protein som är viktigt för osteoblasters funktion, 
ökar i tumörcellerna genom samspelet med osteoblaster. Denna ökning av 
RUNX2 visas vara en nyckel till tumörcellernas förmåga att bilda 
könshormoner. I det avslutande arbetet utvärderas effekten av tasquinimod, 
en läkemedelskandidat, på den osteoblastiska tumörtillväxten av CRPC i ben 
genom den etablerade modellen. Detta läkemedel visade sig effektivt hämma 
bildandet av tumörer i skelettet genom att förändra egenskaper i benmiljön 
samt   genom   att   angripa   osteoblaster   i   det   området   i   skelettet   där 
tumörcellerna helst etablerar sig för att bilda metastaser. 
 
Sammantaget visar denna avhandling att osteoblaster har en nyckelroll i 
benmetastaser av prostatacancer genom att anpassa tumörcellerna till miljön i 
skelettet, samt bidra till en kastrations-resistent tumörtillväxt genom att öka 
den egna produktionen av könshormon i tumörcellerna. Behandling med en 
läkemedelskandidat, tasquinimod, blockerar etableringen av tumören i 
skelettet genom att bland annat angripa osteoblaster i benmiljön. En potentiell 
framtida behandlingsstrategi skulle kunna vara att kombinationsbehandla 
prostatacancer med kastrationsbehandling och läkemedel som angriper 
osteoblaster och därmed förhindra metastasering till skelettet. 
Sammanfattningsvis visar detta avhandlingsarbete att osteoblaster utgör en 
potentiell måltavla för behandling vid prostatacancer. 
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INTRODUCTION 
 
GENERAL BACKGROUND TO PROSTATE CANCER 
Incidence, cause and implications 
Prostate cancer is the most common malignancy in men in Western countries 
and represents the second leading cause of cancer-related deaths [1]. The 
incidence of prostate cancer has increased during the last decades probably 
due  to  longer  life  span, but  also  due to  the  introduction  of the  prostate 
specific antigen (PSA) test in the clinic [2]. Despite good prognosis and 
recent advance in the management of locally defined disease, prostate cancer 
accounts for the highest death rate of cancer in Sweden (Cancer incidence in 
Sweden 2014, Socialstyrelsen). The vast majority of prostate cancer deaths 
are related to castration resistant bone metastases. 
 
Prostate cancer is a highly heterogeneous disease in aging men, and the 
majority of cases occur in men over 60 years of age [3]. The cause of prostate 
cancer is multifactorial and several risk factors have been implicated in 
development  of  the  disease.  Epidemiological  studies  show  that  prostate 
cancer incidence and mortality incidence is highest in the US and Northern 
Europe with Sweden at the top – and lowest in Asia.  Diet and lifestyle seem 
to influence the risk of prostate cancer development [3], and this is supported 
by the fact that US immigrants of Asian origin will eventually develop the 
same  risk  of  prostate  cancer  as  Americans.  In  addition  several  genes 
associated with prostate cancer have been identified [4-6], suggesting that 
genetic background might also be a risk factor. 
 
Diagnosis and prognosis 
In most cases, primary prostate cancer does not present with symptoms, and 
the cancer is detected by routine blood tests where elevated PSA levels might 
be indicative of cancer. There is an ongoing debate on the benefit of PSA 
testing due to its limited diagnostic specificity and low predictive value [7-9]. 
Traditionally, a PSA serum value < 3 ng/mL is considered normal and a PSA 
value > 10 ng/mL indicates a substantial risk of prostate cancer.   A PSA 
value > 100 ng/mL indicates metastatic disease[10]. After a positive PSA 
test, digital rectal examination is performed to find a potential tumor and 
ultrasonography-guided biopsies are taken for histological examination to 
verify the diagnosis. 
Malin Hagberg Thulin 
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The  Gleason  system  is  used  to  grade  tumors  histologically  from  tissue- 
derived biopsies, and this system classifies tumors from 2-5 where 5 is the 
most malignant grade [11]. An overall Gleason score is the sum of two 
Gleason grades, the first is the most common grade in all samples and the 
second is the highest grade of what is left.   The most common clinical 
classification  system  is  the  TNM  (tumor,  lymph  node,  and  metastasis) 
system. The TNM classification system takes into account tumor volume, 
number of lymph nodes involved, and whether there are distant metastatic 
lesions. According to the TNM system, T1 and T2 stage tumors are still 
confined to the prostate. In stage T3 and T4, the tumors are locally advanced, 
and might have spread to organs outside the prostate (Union for International 
Cancer Control).  In case of suspected metastasis, further investigations to 
determine metastatic spread are performed with bone scintigraphy, magnetic 
resonance imaging (MRI), computed tomography (CT) and sometimes 
positron emission (PET)/CT. 
 
The prostate – anatomy and function 
The prostate gland is a walnut shaped exocrine organ located in front of the 
rectum, below the urinary bladder, and surrounding the urethra. The main 
function of the prostate is to produce and secrete an acidic fluid consisting of 
proteins important for sperm motility and viability. The most abundant 
proteins found in secretions of the prostate are PSA and prostatic acidic 
phosphatase (PAP), both of which are used as clinical markers for prostate 
cancer. The prostate can be divided into three distinct zones: the peripheral, 
central and transitional zones [12]. The majority of benign prostatic 
hyperplasia lesions occur in the transitional zone, while most cancer arises in 
the peripheral zone [13-15] (Figure 1A). 
 
Morphology of the normal and the malignant prostate 
The prostate gland is enclosed by a fibromuscular capsule surrounded by 
stromal tissue. The prostate consists of three different cell types of epithelial 
origin, the luminal cells, the basal cells and the neuroendocrine cells. The 
luminal cells constitute the majority of cells and are terminally differentiated, 
express androgen receptor (AR) and require androgens for survival [16, 17]. 
Basal  cells  express  low  or  no  levels  of  AR  and  are  not  dependent  on 
androgens for survival and growth [16, 18, 19]. It is believed that the basal 
membrane harbors stem cells or progenitor cells that can proliferate and 
differentiate into luminal cells in the presence of androgens and can re- 
populate the luminal layer if needed [20-23]. The neuroendocrine cells 
represent a small population differentiated AR negative cells [24, 25]. 
Malin Hagberg Thulin 
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Figure 1. Anatomy and morphology of the normal and malignant prostate A) Illustration of 
the prostatic zones. Prostate cancer most often arises from the peripheral zone (d) whereas 
benign prostatic hyperplasia mainly develops in the transitional zone (c).  B) Illustration of the 
cellular composition of the normal prostate and C) in primary prostate cancer. The distinct 
cell layers and cell compositions are rearranged in the primary tumor of prostate cancer. 
Adapted and modified from [26] and [27]. 
 
The surrounding stroma is biologically heterogeneous and composed of 
smooth muscle cells, endothelial cells, nerve cells, fibroblasts, dendritic cells 
and infiltrating immune cells along with growth factors, cytokines and 
numerous extracellular matrix (ECM) components.  Fibroblastic stromal cells 
express AR and are androgen responsive [28-30]. The fibroblastic stromal 
cells produce growth factors in an androgen-dependent manner and the 
crosstalk between stroma and epithelial cells is an important regulator of 
prostate growth and differentiation [31]. 
 
In the malignant prostate, there exists a communication between prostate 
tumor cells and the stromal cells [18]. Interactions via paracrine signaling 
between tumor cells and stroma factors released from the tumor 
microenvironment are required for invasion, angiogenesis and metastasis of 
cancer cells to ectopic sites [19-21]. It is therefore generally believed that the 
stroma cells are important regulators of prostate cancer initiation and 
progression. 
 
Endocrine regulation and growth of the normal and malignant prostate 
The development, growth and function of the prostate are strictly dependent 
on androgens. Androgenic action in the prostate is primarily mediated by 
dihydrotestosterone (DHT), which is derived predominantly from the 
reduction of testosterone (T) or indirectly via adrenal dihydroepiandrosterone 
(DHEA). The cellular response to androgens is mediated via AR. Both T and 
DHT can bind to AR but DHT has stronger binding affinity and is thus a 
Malin Hagberg Thulin 
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more potent metabolite [32]. The catalysis of T to DHT occurs by locally 
produced 5 alpha- reductases (SRD5A) in the epithelial and stromal cells of 
the prostate and peripheral tissue [33, 34].  The testicular production of T 
accounts for 90–95% of the circulating androgens, and the remaining 5–10% 
is   produced   by   the   adrenal   glands   [35,   36].   Androgen   levels   are 
predominantly regulated through the hypothalamic-pituitary-adrenal /gonadal 
axis. The production of androgens is regulated by the hypothalamus through 
the secretion of gonadotropin-releasing hormone and the weak androgens – 
androstenedione and DHEA – which stimulate secretion of luteinizing 
hormone from the pituitary gland. Secreted luteinizing hormone stimulates 
the   Leydig   cells   to   produce   and   secrete   T   [36].   In   addition,   the 
corticotrophin-releasing hormone released by the hypothalamus induces 
secretion of adrenocorticotropic hormone in the pituitary gland. 
 
Treatment of prostate cancer 
For localized prostate cancer, treatment methods such as surgery (radical 
prostatectomy) or radiation therapy can often cure the cancer. If the cancer is 
detected  early  and  the  life  expectancy  of  the  patient  is  long,  active 
surveillance might be an initial option. For patients with locally advanced and 
metastatic prostate cancer, there is currently no cure and the therapy is given 
in the form of castration therapy.  Androgen deprivation therapy (ADT)  has 
been the mainstay of treatments for advanced prostate cancer since the 
recognition  of  the  disease  as  being  androgen-sensitive  by  Huggins  and 
Hodges in 1941 [37]. The clinical use of ADT include medical therapies such 
as luteinizing hormone-releasing hormone agonist/antagonists or estrogens 
that target the hypothalamic-pituitary-gonadal axis [37], and this treatment 
leads to “chemical castration” with suppression of T from the testis and direct 
inhibition  of  AR  action  for  patients  with  locally  advanced  disease  or 
metastatic prostate cancer. The efficacy of ADT is based on achieving 
castration levels of serum T, defined as < 20ng/dL. This approach initially 
results in a beneficial suppression of tumor growth as evidenced by decreased 
tumor burden, decreased PSA levels and regression of symptoms in the 
majority of patients. However, regardless of the timing and nature of ADT, 
relapse  of  castration-resistant  disease  (CRPC)  with  bone  metastases  will 
occur. Despite initial good response to ADT, the majority of patients will 
experience disease progression/relapse within 24 months as evidenced by 
increasing  PSA,  radiological  progression  and/or  progression  of  disease- 
related symptoms [38-40]. The mechanisms contributing to the development 
of castration resistance in metastases are not clear. However, it is known that 
acquired resistance to ADT often coincides with progression of metastasis to 
bone tissue [41]. Although prostate cancer also metastasizes to lymph nodes, 
these metastases are seldom resistant to therapy, suggesting that prostate 
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cancer has a unique relationship to the prostate and bone microenvironments 
[42, 43]. An adverse effect of castration/ADT is the negative effect on bone. 
In fact, studies have shown that men receiving ADT are four times more 
likely to develop significant bone deficiency [44]. 
 
The AR is composed of three domains. The COOH-terminal ligand binding 
domain  binds  androgens  and  anti-androgens,  such  as  bicalutamide.  The 
ligand  binding  domain  of  the  AR  contains  a  weak  activation  function-2 
region and is separated from the highly conserved DNA binding domain by a 
hinge  region  that  mediates  nuclear  localization  [45].  The  DNA  binding 
domain  is  centrally  located  in  the  AR  and  binds  to  androgen  response 
elements in upstream regulatory regions of androgen regulated genes, such as 
PSA. The NH2-terminal domain [46, 47] is the most variable in terms of 
sequence homology between species and contains the activation function-1 
region required for transactivation (reviewed in [48]). The inactive AR is 
predominantly located in the cytoplasm bound to heat shock proteins [49]. 
Upon ligand binding, cytosolic AR undergoes conformational changes 
including interactions between the C-terminal and N-terminal domains and 
dissociation from the heat shock protein, and this enables interactions with 
co-regulatory factors such as ARA70 [50]. The transformed AR undergoes 
dimerization, phosphorylation and translocation into the nucleus [51]. In the 
nucleus the AR dimer binds to androgen response elements located in the 
promoter or enhancer region of AR target  genes [52], and it recruits various 
co-activators and RNA polymerase II to induce the transcription of AR- 
regulated genes needed for normal prostate function [53-55]. 
 
 
CASTRATION RESISTANT PROSTATE CANCER 
 
It has also become evident that CRPC tumors are not androgen-independent 
because reactivation of the AR is frequently found in CRPC [56] and 
intratumoral androgen levels are maintained as levels sufficient to activate 
AR signaling pathways [34, 57-60]. Despite the fact that castration leads to 
low levels of circulating T (<50 ng/dL), castration does not eliminate 
androgens from the prostate tumor microenvironment.  It has been shown that 
DHT and T in castrated men with locally recurrent CRPC are further elevated 
relative to serum levels, while tissue T levels in metastatic CRPC might 
actually be higher than in the prostate prior to castration [34, 60-62].  Several 
mechanisms by which prostate cancer cells can escape ADT, and restore AR 
activity have been described [48, 63]. The AR might become hypersensitive 
to DHT, it might become activated by other ligands than DHT, or it might 
become activated in the absence of a ligand. Furthermore, androgen signaling 
pathway might be completely by passed, or the tumor cells might begin to 
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express enzymes enabling the de novo synthesis of intratumoral androgens 
invoking an autocrine or paracrine mechanism for the development of CRPC 
[51, 64, 65]. 
 
Studies have shown that 20–30% of locally recurrent CRPC tumors harbor 
AR amplification [66-68]. Increased expression of AR enables AR-mediated 
signaling   even   at   extremely   low   levels   of   DHT   [51,   56,   69].   AR 
amplifications are rarely seen in hormone naïve prostate cancer, suggesting 
that amplification is selected for during emergence to CRPC. In addition, AR 
splice variants lacking the ligand binding domain are proposed to be 
constitutively activated [70]. AR regulates gene expression through 
recruitment of co-regulators complexes, and these co-regulators might act to 
enhance transcription or to suppress transcription of AR target genes [71, 72]. 
In vitro studies have shown that changes in components of the co-regulatory 
complex can modulate AR stability leading to an increase in overall AR 
activity and to broadened ligand specificity, in particular at low androgen 
levels [73]. Several co-activators such as members of the SRC family (SRC- 
1, SCR-2/TIF-2, SRC-3), TIP60 and ARA70 have been reported to be 
increased in CRPC [74-77]. The AR can also be activated in an androgen- 
independent manner by a number of factors, including interlekin-6 (IL-6), 
insulin growth factor-1 (IGF-1), epidermal growth factor (EGF) and cAMP 
[78-80]. Because the bone environment harbors many of these growth factors 
it has been suggested that bone-derived factors might facilitate the survival of 
prostate cancer and its progression to androgen independence by cross talk 
with the AR and alternative signal transduction pathways [81-83]. For 
example, soluble factors derived from osteoblasts have been shown to bind 
and transactivate AR, suggesting that AR might play a role in the progression 
of prostate cancer by a mechanism initiated by factors secreted from 
osteoblasts [84, 85]. 
 
Intratumoral androgen synthesis 
There seems to be a gradual shift during prostate cancer progression from 
dependence   on   androgens   from  endocrine   sources   to   dependence   of 
androgens from paracrine, autocrine and intracrine sources [86].  Metastatic 
CRPC display a pattern of up-regulated steroidogenic enzymes, which could 
explain the elevated local levels of DHT and T found in bone metastases [60, 
65, 87-89]. Intratumoral steroidogenesis might be initiated  either via the 
uptake of weak adrenal gland precursors from DHEA [90] or via de novo 
steroidogenesis from cholesterol (Figure 3) [64, 91]. 
 
Several studies have identified increased expression of enzymes mediating 
the synthesis of T and DHT from weak adrenal gland precursors. Among 
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these the expression of AKR1C3, SRD5A1 and HSD3B2 have been reported 
in bone marrow biopsies of CRPC [60, 65, 87]. Besides the ability of prostate 
cancer cells to utilize weak adrenal androgens for adaptation to ADT, it has 
now been shown that cholesterol synthesis might be increased in CRPC [92, 
93]. In a recent study investigating the metabolomics in CRPC bone 
metastases, increased cholesterol was demonstrated in bone metastatic tissue 
of   CRPC   [94].   Whether   CRPC   cells   can   synthesize   physiologically 
significant amounts of androgen de novo from cholesterol is less clear. 
However,  the  enzymes  required  for  de  novo  steroid  synthesis  including 
CYP11A1, CYP17A1 and HSD3B1/2 have been detected in metastatic CRPC 
bone marrow biopsies [65, 88, 95]. 
 
 
Figure 2. Androgen synthesis pathways in prostate cancer. Pathways that might contribute to 
androgen synthesis in CRPC are outlined. Redrawn and modified from [96] 
 
Several reports have also shown increased expression of CYP19A1, which 
indicates increased synthesis of E2 from T [97, 98]. In addition, studies on 
CRPC bone metastases have shown increased expression of UDP 
glycosyltransferase 2, B15 (UGT2B15), which in conjunction with UGT2B17 
mediates glucuronidation of DHT metabolites [65]. Together these 
observations strongly suggest that the increased expression of androgen- 
metabolizing genes within metastatic castration-resistant tumors might 
contribute to the outgrowth of castration-adapted tumors (reviewed in [99]). 
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Androgen receptor mutations 
AR mutations are rarely found in the early phase of prostate cancer [100, 
101] but they are highly prevalent in advanced and metastatic CRPC, 
especially in those treated with ADT [102], suggesting that AR mutations 
play a role in tumor progression [102, 103]. In a recent summary of 27 
studies, it was reported that AR mutations ranged from 10% to 40% in CRPC 
compared to 2% to 25% in androgen sensitive tumors [72]. Most of the 
mutations are found in the ligand binding domain, and these mutations result 
in broadened ligand specificity that allows binding of non-androgen ligands 
such as DHEA progesterone, estrogen and cortisol [104-108]. The most 
frequently reported mutation in prostate cancer is a substitution of threonine 
to alanine at amino acid 877 (T877A). This point mutation was initially 
described in the LNCaP cell line [109] and has also been found in clinical 
samples [110]. 
 
 
BONE METASTASIS IN PROSTATE CANCER 
 
It has long been recognized that primary cancers spread to distant organs with 
characteristic preferences [111] and the skeleton is a major metastatic site of 
several carcinomas. In this regard, prostate and breast cancers are the most 
common malignancies that metastasize to bone, hence they are referred to as 
osteotropic cancers. Metastases to bone occur in about 70% of all patients 
with  prostate  and  breast  cancers.  Bone  metastases  represent  98%  of 
malignant bone tumors and are the most frequent occurring metastasis 
occurring in prostate cancer [112]. Around 90% of patients with metastatic 
prostate  cancer  will  develop  bone  metastases.  For  these  patients,  the 
prognosis will be dramatically changed, and there will be increased morbidity 
and a drastic fall in survival expectancy. Once tumor cells have entered the 
bone prostate cancer cannot be cured [113]. As a result the majority of men 
with CRPC die from bone metastatic disease within 2 – 3 years [114]. In 
every second patient bone metastases lead to so-called skeletal-related events 
(SREs), which include pathological fractures, spinal cord compression and 
severe bone pain requiring palliative radiotherapy, and/or orthopedic surgery 
and subsequently an impaired health-related quality of life and reduced 
survival [115]. 
 
Bone metastases behave differently depending on their tumor origin. 
Typically, breast and lung cancer form osteolytic metastases due to enhanced 
activity of bone-resorbing cells, the osteoclasts, resulting in increased bone 
degradation [116-119]. Bone metastases from prostate cancer are 
predominantly characterized by increased bone mass due to the exaggerated 
activity of the bone-forming cells – the osteoblasts. These types of tumors are 
Malin Hagberg Thulin 
20 
 
 
 
referred to as osteosclerotic or osteoblastic [117, 118, 120-123]. This unique 
phenotype suggests that osteoblasts are of particular importance for the bone 
metastatic disease of prostate cancer. 
 
Bone – a mineralized tissue 
Bone provides structural and protective functions and stores calcium, and the 
bone marrow is the major hematopoietic organ, and a primary lymphoid 
tissue. Bone tissue consists of a fibrillous network made up of collagens and 
non-collagenous proteins. The main component is type 1 collagen (COL1A1) 
which accounts for 95% of the extracellular bone matrix and the remaining 5 
% includes a variety of non-collagenous proteins such as bone morphogenetic 
proteins (BMPs), bone sialoprotein and osteocalcin (OCN). The mineralized 
matrix consist of hydroxyapatite Ca5(PO4)3(OH) and crystal depositions. 
 
Bones are divided into long bones (e.g. the tibia, femur, and humerus) and 
flat bones (e.g., the skull, ileum, and mandible). Both types are composed of 
cortical  (compact)  bone  and  trabecular  (cancellous)  bone.  The  trabecular 
bone is metabolically active and has, in contrast to the compact cortical bone, 
unorganized, porous matrix. The cortical bone is 80 - 90% calcified and 
constitutes the protective layer of bone whereas the trabecular bone is only 15 
- 25% calcified and is located in the interior of the bone, near the ends of the 
bone marrow cavity. Long bones are anatomically divided into three sections; 
epiphysis, diaphysis and metaphysis.  The metaphysis is located just below 
the growth plate near the ends of bone and is mainly composed of trabecular 
bone, surrounded by blood vessels, hematopoietic marrow and fatty marrow 
[124]. 
 
Bone cells 
Osteoblasts are the bone-forming cells and account for 4-6% of the total 
resident cells in the bone.  Osteoblasts are found lining the layer of the bone 
matrix that they are producing before it is calcified. This layer is referred to 
as osteoid, which will mature to form calcified matrix. Osteoblasts arise from 
local mesenchymal stem cells (MSCs), which are the precursors for many 
cell types in the bone that are involved in bone formation, including 
chondrocytes, fibroblasts, myoblasts, adipocyte and neural cells [125]. 
To become osteoblasts the MSCs must undergo a strictly regulated 
differentiation process with sequential steps of proliferation, be committed  to 
pre-osteoblasts  producing  alkaline  phosphatase  (ALP),  and  subsequently 
mature osteoblasts producing osteocalcin and calcified matrix [126]. The 
transcription factors Runt- related transcription factor 2 (RUNX2) and the 
downstream factor osterix are crucial for the commitment of the osteoblast 
lineage and for driving differentiation process to become mature mineralizing 
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osteoblasts. After maturation, osteoblasts undergo apoptosis, remain as bone 
lining cells or become embedded in the bone matrix and differentiate into 
osteocytes. A small fraction remain on the bone surface, becoming flat lining 
cells or become osteocytes (up to 30%) [127]. The BMP, Hedgehog and Wnt 
signaling pathways are three major pathways known to regulate the 
commitment of MSCs to the osteoblast lineage. These pathways are activated 
by for example parathyroid hormone (PTH), parathyroid hormone-related 
protein (PTHrP), fibroblast growth factors, transforming growth factor beta 
(TGF-β), sex steroids, and other hormones (reviewed [128]).  Besides being 
crucial for the bone forming process, osteoblasts have been implicated as a 
key regulator in several physiological and malignant contexts.  Osteoblasts 
participate in osteoclast formation by secreting osteoclast stimulatory factors, 
such as macrophage colony stimulating factor 1 (CSF-1) and the receptor 
activator of nuclear factor κβ ligand (RANKL) on their surface [129]. There 
is also evidence that osteoblasts have an endocrine function (reviewed in 
[130]). Moreover, osteoblasts regulate hematopoietic stem cells (HSCs) in 
the bone marrow niche. Exaggerated osteoblast activity also suggests an 
important role in the bone metastatic process of prostate cancer. 
 
Osteoclasts are specialized multinucleated macrophage-like cells with bone 
resorptive capacity that arise from the HSC monocyte/macrophage lineage. 
Macrophage colony stimulating factor (M-CSF) tumor necrosis factor alpha 
(TNFα) and RANKL are important growth factors that support 
osteoclastogenesis, and they are primarily produced by osteoblasts. The bone 
resorption process by osteoclasts occur by generating an isolated 
microenvironment between the cell’s plasma membrane and the bone surface 
in which matrix mineral is mobilized in an acidic milieu, and the organic 
matrix is degraded by the lysosomal protease cathepsin K. Osteoclasts are 
important for the development of osteolytic metastases. 
 
The osteocyte is the most abundant cell type in bone, representing 95% of all 
bone cells in mature bone tissue [131]. Osteocytes arise at the end of the 
mineralization phase from the osteoblast lineage after its entrapment in bone 
matrix [132, 133]. Osteocytes produce sclerostin [134] and are believed to 
play a primary role in directing bone remodeling via RANK/RANKL. 
However the impact of osteocytes in osteoblast regulation is controversial 
and not fully characterized (reviewed in [135]). The role of osteocytes in 
prostate cancer remains to be investigated. 
 
Bone remodeling 
Bone remodeling is a continuous process that is vital to maintain calcium 
stores  and  bone  homeostasis  [136].  Under  physiological  conditions,  the 
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number and activity of osteoclasts and osteoblasts are balanced so that the 
bone resorption and formation is equivalent. The remodeling occurs in so 
called basic multicellular units, in which both osteoclasts and osteoblasts co- 
operate in a remodeling cycle [137-139]. This cycle starts with recruitment of 
monocytes to the bone surface. Osteoblast secreted RANKL binds to the 
RANK receptor on the surface of monocytes to form pre-osteoclasts. In the 
presence of CSF-1, RANKL further promotes the fusion of pre-osteoclasts to 
become mature multinucleated osteoclasts. The osteoclast starts resorption by 
digesting the mineralized matrix. At the end of the resorption phase pre- 
osteoblasts migrate to the resorption site where they mature and start forming 
new bone by producing matrix (osteoid), which is subsequently mineralized. 
A network is formed in the bone by the osteocytes, osteoblasts and bone 
lining cells, and this network responds to signals such as mechanical load and 
specific metabolic and hormonal requirements. These signals are integrated 
in the basic multicellular units leading to a controlled remodeling process. 
 
Bone remodeling is regulated both systemically and locally. The major 
systemic  regulators  include  PTH,  calcitriol,  glucocorticoids  and  estradiol 
(E2). It is now well known that this process can be corrupted by tumor cells 
and associated immune cell infiltrates to provide a favorable growth 
environment for bone metastases [116, 140]. The role of the OPG/RANKL 
system has been studied in patients with osteotropic tumors such as those 
from breast, lung and prostate in relation to their bone metastatic phenotype. 
Osteolytic tumors appear to exert their osteolytic actions through the up- 
regulation of the OPG /RANKL system, whereas prostate cancer seems to 
provoke  profound  elevations  of  OPG,  thus  promoting  a  shift  toward 
increased osteoblastic activity [141]. 
 
The vicious cycle of prostate cancer bone metastases 
The reciprocal communication between tumor cells, bone cells and the bone 
microenvironment   fuels   a   vicious   cycle   of   tumor   growth   and   bone 
remodeling. The phenomenon referred to as “the vicious cycle” was first 
coined in the context of breast cancer metastases by G. Mundy [142] et al in 
1997, and this term described  the cross talk in osteolytic tumors.  Once the 
tumor cells enter the bone, growth factors will be released from the bone 
matrix. The bone matrix is a store house of latent growth factors such as IGF- 
1,  TGF-β,  BMPs,  and  vascular  endothelial  growth  factor  (VEGF).  The 
release of these factors during bone remodeling might promote homing of 
tumor cells to the bone, and stimulate the colonization and proliferation in the 
bone marrow. Depending on the tumor phenotype either osteolytic or 
osteoblastic factors will be secreted. The mechanisms through which prostate 
cancer cells promote osteoblastic growth and bone mineralization remain 
Malin Hagberg Thulin 
23 
 
 
 
poorly understood. However, a variety of bone-stimulating factors produced 
by CRPC cells, including PSA, endothelin-1 (ET-1), BMPs, IGF-1, and OPG 
have direct and indirect effects on bone [143-147] (Figure 3). 
 
 
 
 
 
 
Figure 3. Illustration of the vicious cycle of prostate cancer bone metastases. Depending on 
which factors that are released from the tumor cells either osteoclasts or osteoblasts will be 
activated. OCs = osteoclasts, OBs = osteoblasts. Modified and redrawn from [148] 
 
Hormonal regulation of bone 
Steroid hormones are the key regulators of bone growth and homeostasis 
[149]. In the human male, both androgens and estrogens are involved in 
modeling and remodeling of the skeleton. Male skeletal androgen action can 
be mediated directly through activation of the AR, but also indirectly through 
DFWLYDWLRQ RI HVWURJHQ UHFHSWRU DOSKD ((5Į) YLD &<319$1 IROORZLQJ 
aromatization into estrogens [150]. The direct role of androgens in bone is 
less clear, but AR signaling in osteoblasts has been reported to be important 
to maintain the trabecular bone mass [151, 152]. The direct role of E2 is to 
inhibit bone resorption by affecting osteoblast secretion, including increased 
23* DQG  GHFUHDVHG  5$1./  DQG  71)Į [153-157]. E2 has been shown to 
inhibit bone resorption by promoting apoptosis and differentiation of 
osteoclasts [152, 158]. In addition, it has also been proposed that E2 induce 
the commitment of precursor cells to the osteoblast lineage at the expense of 
the adipocyte lineage and to prevent osteoblast apoptosis [137, 159, 160]. 
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Bone tissue and osteoblasts express steroid receptors and all enzymes 
necessary to convert the adrenal androgen precursors DHEA and 
androstenedione into active androgens and estrogens [161]. This provides 
significant evidence that bone is an endocrine organ with local paracrine 
and/or intracrine synthesis and a site of actions for steroids. Men receiving 
ADT  have  reduced  bone  mineral  density  (BMD)  and  increased  risk  of 
fracture because of significantly suppressed levels of serum T and E2 
(reviewed in [162]).  Due to the absence of androgens and estrogens the 
balance of bone turnover will shift towards bone degradation. In this process 
growth factors that have been embedded in the bone matrix are released, and 
these factors can function as chemotactic stimulants for prostate cancer cells, 
hence supporting their invasion, colonization and proliferation in the bone 
niche [116, 120, 163]. 
 
Osteotropism 
The proclivity for prostate cancer cells to metastasize to bone has been 
explained by several mechanisms. The retrograde flow of tumor cells through 
Batson´s venous plexus is the main anatomical explanation of the route for 
metastatic spread [164, 165].  In addition to anatomy, the British pathologist 
Stefan Paget published the seed and soil theory in the Lancet in 1889 [111]. 
After analyzing over 900 autopsies comparing primary breast cancer tumors 
with their metastases, Paget proposed that metastasis does not occur by 
chance, but depends on cross-talk between selected cancer cells (the 'seeds') 
and specific organ microenvironments (the 'soil'). In other words, certain 
tumor cells will selectively colonize to distant organs because of the presence 
of a favorable microenvironment for their localization and growth. Paget 
compared the seeding of cancer cells to the dispersal of the seeds of plants: 
 
“When a plant goes to seed, its seeds are carried in all directions; but they 
can only live and grow if they fall on congenial soil”. 
 
Ever since, this theory has remained a basic principle in the field of cancer 
metastasis [166, 167] and is particularly relevant to bone metastasis because 
osteotropic cancer cells possess certain properties that enable them to grow in 
bone, and the bone microenvironment provides a fertile soil in which they 
grow  [128].  The  seed  and  soil  theory  was  reinforced  in  recent  studies 
showing that the acquisition of specific gene expression profiles [168] or the 
activation of specific signaling pathways [169, 170] dictates the specificity of 
cancer cells growing in bone. 
 
Bone provides an especially attractive site for a variety of reasons. The 
continuous  and  dynamic  turnover  of  the  bone  matrix  and  bone  marrow 
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provides a fertile soil for tumor cells. The osteoblasts, as well as the marrow 
cells, provide an environment rich in growth factors, cytokines and 
chemotactic factors. As already mentioned certain areas of the bone are 
metabolically active – such as the metaphysis at the ends of the long bones – 
and these are well vascularized and allow various cells to easily enter and exit 
the bone. The vascular supply is sinusoidal in nature rather than a bed of 
capillaries. These factors, and the vascular structure of the trabecular bone, 
are crucial for metastatic cancer cell colonization and growth. Most likely, 
the suitability of bone as a site for metastasis is a mixture of factors involving 
anatomy, properties of the tumor cells, and the composition of the pre- 
metastatic niche in the metastatic site. 
 
The way to the bone – the metastatic process 
Metastasis is the process through which cancer spreads from the original site 
(primary site) to other parts of the body. Overall, metastasis is an inefficient 
process. Of the several millions of disseminated tumor cells (DTCs) that are 
introduced into the circulation, it is estimated that only a very small fraction 
(0.001– 0.02%) succeed in forming metastatic foci [171-173]. The metastatic 
process consists of a long series of sequential, interrelated steps, including 
degradation of the ECM, detachment of the tumor cells from the ECM and 
from each other, and migration toward and subsequent entry into the blood or 
the lymphatic system [174, 175].  Each of these steps can be rate limiting, 
and a failure or an insufficiency at any of the steps can stop the entire process 
[176, 177]. It is believed that the dissemination of tumor cells might occur 
early during progression with tumor cells preferentially homing to bone 
marrow. 
 
Epithelial mesenchymal transition 
For metastasis to occur, tumor cells must first detach and reach the 
vasculature. Several carcinomas including prostate cancer can develop 
invasive and mesenchymal features that facilitate detachment and migration. 
In order to acquire a mesenchymal migratory phenotype, tumor cells must 
shed many of their epithelial characteristics, detach from the epithelial layer 
and undergo a drastic alteration and this is referred to as epithelial 
mesenchymal transition (EMT) [178-180]. 
 
EMT is characterized by loss of cell-cell adhesion, loss of apical-basal 
polarity, and reorganization of the cytoskeleton in a process largely induced 
by tumor infiltrating immune and stromal cells [181]. Therefore tumors are 
often considered to be corrupted forms of normal developmental processes 
and EMT is often considered to be the most fatal consequence in 
tumorigenesis [178, 182-184]. 
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In addition to the loss of epithelial characteristics, EMT frequently coincides 
with the acquisition of motility, invasiveness, changes in the cytoskeletal 
proteins (such as expression of vimentin and α-SMA) altered adhesion 
receptor expression (switching from E-cadherin to N-cadherin (CDH2) or 
Cadherin-11 (Osteoblast-cadherin)) and proteinase secretion (especially 
metalloproteinases (MMPs) [178, 179, 185-189]. In prostate cancer the 
“cadherin switch” has been observed in the more aggressive/castration 
resistant   cell   lines   [190-192].   Supporting   these   data   N-cadherin   and 
Cadherin-11 both have been reported to increase after androgen deprivation 
[192, 193]. Cadherin-11 is known to facilitate the interaction with osteoblasts 
in the bone [193, 194]. 
 
The next step of invasion and metastasis requires disruption of the basal 
membrane and remodeling of the ECM which is coordinated by proteases 
such as MMPs and cathepsins. The acquisition of a mesenchymal phenotype 
by the cancer cells is crucial for invasion of the underlying stromal 
compartment.  This  step  is  considered  to  be  the  as  the  most  critically 
important for malignant progression because this switch facilitates 
dissemination and metastasis. 
 
Detachment, migration, attachment and colonization 
After EMT, prostate tumor cells must go through a multistep process to 
metastasize to bone.  These steps involve detachment from the primary site, 
survival in the circulation, attachment to resident cells in bone, and survival 
and  proliferation  in  the  bone  marrow.  Circulating  prostate  cancer  cells 
(CTCs) preferentially adhere to bone marrow endothelial cells and then 
migrate through the endothelial layer [195] in a process involving several 
adhesion molecules such as selectins, integrins and cadherins that are present 
on the surfaces of endothelial cells and DTCs. The final stages of the 
metastatic cascade involve adhesion to the bone marrow endothelium of the 
sinusoids vessels, extravasation and colonization of bone marrow. 
 
After successful colonization of bone marrow, it has been shown that the 
metastasized bone tumors are largely composed of cancer cells showing a 
mixed epithelial–mesenchymal phenotype and many morphological 
characteristics similar to the primary tumor. This suggests that the metastatic 
bone tumor resembles the primary phenotype in the bone microenvironment 
[188]. It appears that a number of DTCs in the bone marrow can reactivate 
certain properties through a mesenchymal–epithelial transition (MET). At 
present, the role of EMT and MET in bone metastasis is not fully understood, 
but it is known that these transitional stages are strongly affected by the bone 
microenvironment [196]. 
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Osteomimicry 
Besides  undergoing  EMT  to  acquire  mesenchymal  features,  the  prostate 
cancer cells must acquire bone cell-like properties in order to thrive in the 
bone microenvironment [19]. This adaptation is referred to as osteomimicry 
and has been substantiated in animal models and humans [19, 197, 198]. 
This process enables prostate cancer cells to produce bone matrix proteins 
such as osteopontin, osteonectin and bone sialoprotein. The osteoblast 
transcription factor RUNX2 has also been implicated in the osteomimicry 
that is attributed prostate skeletal metastasis (123–125). Osteomimicry 
facilitates the conditions for the tumor cells to metastasize, adhere, survive, 
and grow in bone. However, it is not fully known if the cancer cells already 
possess osteomimetic properties when they detach from the primary tumor 
site, or whether some of these phenotypical changes occurs when the cancer 
cells reach the bone marrow.  Tumor cells in the metastatic prostate lesion 
might transdifferentiate to become mesenchymal cells that are capable of 
osteoblastic activity, cancer cells might induce resident cells in the marrow 
microenvironment to enter the osteoblast lineage, and prostate cancer cells 
might  induce the  proliferation and/or  differentiation of osteoblast lineage 
cells.  Osteoblasts  are  a  vital  component  in  certain  aspects  of  tumor 
localization in bone [199]. 
 
The bone metastatic niche and tumor cell dormancy 
The concept of a pre-metastatic niche has emerged as a means through which 
a primary tumor is able to prepare sites of metastasis [199]. Primary tumors 
might  condition  the  bone  marrow  through  the  production  of  circulating 
factors that target cells in the bone microenvironment and thus render it 
capable of facilitating tumor localization and colonization. 
 
Preclinical evidence suggests that DTCs can home in and localize in the HSC 
niche and that they survive in a dormant state. During dormancy the DTCs 
either stop proliferating or they proliferate at a reduced rate before showing 
clinical  evidence  of  metastasis.  The  period  of  dormancy  can  sometimes 
exceed 10 years [200-204]. Patients with bone marrow DTCs at diagnosis are 
at a higher risk of both skeletal and extraskeletal metastasis. Evidence exists 
that DTCs can persist in the bone marrow for years in a quiescent state and 
that these cells are resistant to cancer therapies [205-207]. Of patients with 
prostate cancer who have had a radical prostatectomy, 72% have DTCs in the 
bone marrow [208].  However it is still a matter of debate whether the DTCs 
actually form metastasis or whether they prepare the metastatic niche for 
tumor establishment. 
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Bone marrow comprises various cell types, including cells of hematopoietic 
origin and cells involved in bone formation and remodeling. In the bone 
marrow osteoblasts, endothelial cells, adipocytes, nerve cells and 
mesenchymal stem cells serves as a niche for HSCs and maintain the activites 
of HSCs such as homing, self-renewal, quiescence and differentiation. Recent 
evidence indicates that a subset of osteoblasts, named Spindle-shaped N- 
cadherin positive osteoblasts, plays an important role the regulation of HSCs 
[209]. In particular, these specialized osteoblasts are located next to the 
endosteal  surface  of  bone –  the  osteoblast  niche  – where  they have  the 
specific function of maintaining the HSCs in a quiescent state. This is 
supported by the finding that conditional ablation of osteoblasts in mice leads 
to depletion of HSCs [210], while stimulation with PTH increases the number 
of HSC and the number of osteoblasts [209]. Malignant cells disseminate to 
and develop in the bone marrow by hijacking the osteoblastic niche [211, 
212]. In fact, both prostate and breast cancer home to the marrow by 
mimicking the homing mechanisms of HSCs (Figure 4) [213, 214]. 
 
 
 
 
 
Figure 4. Illustration of the osteoblastic pre-metastatic niche in the bone marrow. Prostate 
cancer  cells  and  HSC  home  to  osteoblasts  in  the  bone  marrow  (niche)  using  similar 
mechanism. HSC = hematpoetic stem cell, SNOs = Spindle shaped N-Cadherin (Cdh2) 
expressing osteoblasts, DTC = Disseminated tumor cell. Redrawn and modified from 
http://www.sciencedaily.com/releases/2011/03/110323140237.htm 
 
As a result of this competition for the niche, disseminated prostate cancer 
cells displace HSCs from the marrow and induce the differentiation process 
of HSCs into hematopoietic progenitor cells (HPCs). Correspondingly, high 
levels of HPCs can be detected in the peripheral blood of prostate cancer 
patients with bone metastases. The mechanisms behind this phenomenon are 
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not clear, but several types of intercellular communication have been 
proposed, including exosomes containing mRNA, protein, or microRNA that 
are released by the tumor cells. The SDF-1/CXCR4 axis is considered to be 
important for tumor cell homing to bone [168, 214-216]. The homing into 
and the retention of HSCs, MSCs, as well as osteotropic cancer cells to the 
bone marrow niche is mediated by their expression of CXCR4, one of the 
receptors of the chemokine CXCL12 or stromal derived SDF-1α expressed 
by osteoblasts [213, 217, 218]. The capability of tumor cells to mimic HSC 
cells, and evidence for factors that induce HSC dormancy could explain 
tumor cell dormancy in bone marrow niches. In addition, osteoblasts and 
endosteal cells express annexin II (anxa2) which activates the growth arrest- 
specific  6  (GAS6)  receptors  on  prostate  cancer  cells.  Differential  levels 
GAS6 protein in the bone microenvironment induce dormancy in HSCs and 
has been found to reduce cell cycle progression in prostate cancer cells[219]. 
This evidentially shows that osteoblasts are facilitators for tumor dormancy 
in bone [220].  Similarly, homing was decreased when osteoblasts lacked the 
expression of annexin II (anxa2) in mice. Moreover, both HSC and prostate 
cancer cells express Anxa2 receptor (Anxa2r) and knockdown of this in 
prostate cancer cells decreased their homing to bone [221, 222]. Shiosawa et 
al further demonstrated that prostate cancer cells and HSCs both are co- 
localized in mouse bone marrow, next to cells expressing RUNX2 [221], 
supporting that prostate cancer cells   are homing preferentially to the 
osteoblastic niche. In another study, metastasis to bone was decreased when 
osteoblasts were depleted in a transgenic mouse model, hence demonstrating 
an important role of osteoblasts in metastasis to bone. 
 
Osteoimmunology and bone metastases 
The immune system has long been known to play an important role in 
preventing tumor growth, but more recent evidence suggest the importance of 
the immune cell response to factors in the tumor microenvironment as main 
regulator of cancer progression and metastases. The fact that only a small 
fraction  of  DTCs  succeed  in  colonizing  the  distant  microenvironment 
suggests that the rate-limiting steps occur along the metastatic cascade after 
extravasation. These steps include angiogenesis, the establishment of a 
favorable growth promoting niche and evading immunosurveillance, in the 
bloodstream and in the bone [223, 224]. 
 
Bone marrow comprises marrow stem cells; the MSCs that give rise to 
osteoblasts and osteocytes, and the HSCs that develop into both myeloid 
derived suppressor cells (MDSCs) that differentiate into osteoclasts and 
lymphoid progenitors that give rise to immune cells. Moreover, recent studies 
have also indicated that certain cell of the immune system can help tumor 
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cells to become established within a niche. The bone marrow is a reservoir 
for immune cells such as macrophages, dendritic cells (DCs), MDSCs, B- 
cells and different T cell subsets that can directly impair the so called 
“tumor/bone vicious cycle” as reviewed in [225]. A hallmark of advanced 
bone  metastasis is the prevalence of immunosuppressive cell populations 
such as MDSCs and regulatory T-cells. During tumorigenesis, the secretion 
of several factors such as IL-4, IL-13, VEGF, granulocyte–macrophage 
colony-stimulating factor (GM-CSF), granulocyte-colony-stimulating factor 
(G-CSF) and TGF-β leads to the expansion, activation and recruitment of 
MDSCs, which might increase up by to 25% in patients with bone metastases 
[226]. The MDSCs have multiple roles in immune suppression such as 
stimulating osteoclastogenesis [227, 228]. Moreover MDSCs supports the 
polarization of macrophages into a tumor-promoting phenotype [226] and the 
establishment of the pre-metastatic niche. Macrophages are like DCs and 
osteoclasts derived from circulating CD14+ monocytes, which originate from 
bone marrow myeloid stem cells [229]. Macrophages are frequently found in 
the marrow, where they help establish a favorable tumor microenvironment. 
These macrophages are referred to as tumor-associated macrophages (TAMs) 
and they have a significant amount of e plasticity that allows them to 
effectively respond to environmental changes [230-232]. Based on the 
activation route, TAMs can generally be divided into two major phenotypes: 
M1 tumor-inhibiting macrophages and M2 tumor-initiating macrophages. 
TAMs are suggested to play a pivotal role in the process of primary tumor 
growth, dissemination of cancer cells, and subsequent metastasis through the 
release of inflammatory cytokines and proteases such as cathepsin K [233, 
234]. Moreover, it was shown that primary prostate tumor cells distantly 
instigate osteoblasts via PTHrP in the systemic circulation to increase the 
production of pro-metastatic VEGF (A), IL-6 and CCL-2 in the bone 
microenvironment which in turn stimulate MDSCs with increased angiogenic 
potential [230]. 
 
Although bone already represents an immune privileged site, tumor cells can 
further skew the balance of immune effector and suppressor cells towards an 
immunosuppressed niche to promote their outgrowth in bone (reviewed in 
[226]). It is now known that tumor cells can induce an immunosuppressed 
microenvironment in metastatic sites before their arrival via the secretion of 
immunosuppressive  cytokines.  For  example,  tumor  cell  and  bone  cell 
secretion  of  TGF-β  has  been  associated  with  immunosuppression  in  the 
tumor microenvironment [235, 236]. Recent evidence supports a role of 
osteoblasts in osteoimmunologi by their release of cytokines and growth 
factors in the microenvironment [237]. 
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Pathophysiology of prostate cancer bone metastases 
Many patients with prostate cancer have bone metastases that appear on 
radiography as lesions with areas of increased bone density and on bone scan 
as hot spots of increased bone formation. Histopathological assessment of 
prostate cancer bone metastases show increased abnormal bone formation, 
with an elevated osteoid surface, i.e., unmineralized matrix.  Osteoblastic 
lesions are composed of increased abnormal woven bone that is formed in 
marrow spaces from the tumor stroma and not from the bone surface [238]. 
Moreover,   these   metastases   typically   show   an   excessive   number   of 
osteoblasts adjacent to tumor cells. In contrast, osteoblasts are  generally 
absent in bone metastases from other cancers (such as breast, lung and 
kidney),  which  instead  are  dominated  by  osteoclasts  [43].  Although  the 
overall tumor response of prostate cancer is osteoblastic, large heterogeneity 
of bone histomorphometry is seen in the same patients comprising lesions of 
both  osteoblastic/osteolytic  areas. The  histological findings  are  consistent 
with clinical evidence that demonstrates increased systemic markers of both 
bone production and degradation in prostate cancer patients [239] 
 
Markers of bone metastases 
The tumor-associated activity can be visualized clinically, via radiographs, 
pathologically or by measurements of bone biochemical markers.  Many 
markers of bone metabolism are elevated in bone metastases and are closely 
related with disease progression and have a prognostic value for diagnosis, 
determination of treatment and monitoring of treatment efficacy. Biochemical 
markers of bone turnover are generally categorized into bone resorption and 
bone formation markers.  The bone formation markers include bone specific 
alkaline phosphatase (bALP), bone matrix proteins such as OCN and the 
procollagen extension peptides (P1NP and P1CP).   bALP is an enzyme 
specifically produced by osteoblasts that is released into circulation during 
the   mineralization   process   [240].   OCN   is   a   noncollagenous   protein 
synthetized by osteoblasts that binds to hydroxyapatite and is involved in 
calcium binding [241]. P1NP  and P1CP are derived from the extracellular 
processing  of  the  procollagen  type  I  molecule,    which  contains  amino- 
terminal  and  carboxy-terminal  extensions  that  are  enzymatically  cleaved 
upon procollagen secretion [242]. 
 
Bone resorption usually occurs before bone formation, and thus an increased 
level of bone resorption markers might be indicative of bone tumor activity. 
The  clinical  markers  bALP  and  N-telopeptide  of  type  1  collagen  are 
associated with higher rates of death and skeletal-related events in prostate 
cancer bone metastases. Although bone-remodeling markers might be helpful 
in  better  defining  the  prognosis  and  the  risk  for  bone  complications  in 
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patients with bone metastatic disease, the level evidence is not yet sufficient 
to recommend them as part of the guidelines for clinical practice [243]. 
 
Treatment of bone metastatic CRPC 
Tumors  are  generally  incurable  once  they  have  metastasized  to  bone. 
However there are strategies to prolong survival and to manage SREs. The 
first line-therapy for patients with metastatic CRPC after relapse from ADT is 
systemic (chemo) therapy in the form of the cytotoxic drug docetaxel [244, 
245]. Systemic treatment with docetaxel has been used as the standard 
treatment demonstrating both improved quality of live and overall survival 
rates [244]. The second line therapies include chemo therapy with cabazitaxel 
which, like docetaxel, is a microtubule stabilizer [246]. Docetaxel and 
cabazitaxel are taxenes that exert their therapeutic effect by stabilizing the 
microtubules, and thus they block cell division, induce apoptosis and inhibit 
nuclear translocation of the AR [247]. Although chemotherapy has been 
shown to improve overall and progression free survival [246, 248], it is not 
well tolerated by all CRPC patients because the majority are elderly men with 
limited  bone  marrow and  concurrent  medical  conditions  [249].  In  recent 
years, a wide variety of novel therapeutic options have become available for 
patients with metastatic CRPC. These strategies consist of cytotoxic, anti- 
androgen,   immune   and   radiopharmaceutical   therapies.   The   new   anti- 
androgen therapies include abiraterone acetate (Zytiga®) [250] and 
enzalutamide (XTANDI®) [251]. Abiraterone is a highly efficient inhibitor 
of the CYP17A1 complex, thereby making it an androgen synthesis inhibitor 
in the adrenal glands, testes and prostate cancer cells and their 
microenvironment [86].   Treatment with abiraterone requires concominant 
use of prednisone to decrease symptoms of mineralcorticoid excess. 
Enzalutamide is an AR-signaling antagonist that binds to the AR ligand site 
and thereby inhibits nuclear translocation of the AR, DNA binding, and co- 
activator recruitment. Both enzalutamide and abiraterone show beneficial 
effects on CRPC patients with bone metastatic disease [250, 252, 253]. 
 
Another approach to pain relief in patients with bone metastases has been the 
use of radiopharmaceuticals. Strontium, samarium, and radium have strong 
avidity for the calcified matrix of bone. These agents only exert a small 
antitumor effect through localized radiation, but they have substantial effects 
on bone pain [254]. The radioisotope radium-233 (Alpharadin®) is a new 
bone-seeking alpha-emitter radionucleotide that might be added to the 
therapeutic regimen of patients with CRPC who have either received or are 
considered unsuitable for docetaxel treatment. The radiation from the decay 
of  radium-233  kills  tumor  cells  by  inducing  double-strand  breaks,  and 
radium-233   was   recently   reported   to   extend   survival   in   men   with 
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symptomatic CRPC and bone metastases [255]. The bone marrow also serves 
as a reservoir for DTCs that can resist chemotherapy, and these tumor cells 
can emerge later as new metastases in bone or other organs [206, 256]. Drugs 
that directly interfere with bone remodeling, such as bisphosphonates 
(zoledronic acid) and RANKL antibodies, that target osteoclastogenesis have 
shown to significantly decrease the incidence of skeletal complications and 
are the current standard of care for patients with bone metastases regardless 
of symptoms. However, both bisphosphonates and RANKL therapies act to 
inhibit osteoclast-mediated bone resorption and can prevent bone loss in 
patients receiving ADT, i.e., they can indirectly increase BMD [257, 258]. 
There are emerging data that these anti-resorptive agents can also have direct 
anti-tumor effects. However, 30–50% of patients on such therapies still 
develop  new  bone  metastases,  skeletal  complications  and  disease 
progression, emphasizing the need for new therapies. 
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AIMS OF THE THESIS 
 
 
 
GENERAL AIM 
 
Bone metastasis is the major cause of morbidity for men with advanced 
prostate cancer. Once the cancer has entered the bone, there is no cure. 
Prostate cancer forms osteoblastic metastasis – which is rare in other 
osteotropic cancers such as breast cancer – gives rise to predominantly 
osteolytic tumors in bone. The molecular mechanisms of osteoblastic tumors 
are poorly understood, and it is not known how prostate cancer in the bone 
microenvironment develops castration and drug resistance. Therefore, the 
overall aim of this thesis was to investigate the specific role of osteoblasts in 
bone metastatic prostate cancer. 
 
 
 
 
SPECIFIC AIMS 
 
• To develop and characterize a novel model suitable for in 
vitro and in vivo studies of the osteoblastic function of 
CRPC. 
 
 
 
 
• To explore the role of osteoblasts in the development and 
growth of sclerotic CRPC tumors. 
 
 
 
 
• To investigate the specific role of ectopically expressed 
RUNX2 in the growth of osteoblastic tumors. 
 
 
 
 
• To evaluate the effect of a novel therapeutic (tasquinimod) 
on osteoblastic CRPC in bone using the in vitro and in vivo 
model. 
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METHOLOGICAL CONSIDERATIONS 
 
 
 
The methods used in this thesis are based on in vitro experiments to explore 
the role of soluble factors in the bi-directional cross talk between tumor cells 
and osteoblasts and in vivo experiments to verify the findings in a 
physiological context comprising the bone microenvironment. 
 
What follows is an overview and considerations of methods used in this 
thesis. For detailed description of material and methods see the corresponding 
paper. 
 
 
IN VITRO EXPERIMENTS 
 
Cell lines and culture conditions 
Although  cell  lines  used  in  vitro  do  not  recapitulate  the  heterogeneous 
condition in human prostate cancer, utilizing a representative in vitro model 
will spare cost and minimize ethical issues in decreasing the use of animal 
experiments. The cell lines used in this thesis were selected based on their 
specific phenotypic properties in bone. In the in vitro set-up a murine pre- 
osteoblastic cell line was chosen for studies of the bi-directional interplay 
with the human prostate cancer mimicking xenografts in vivo. 
 
For all experiments Minimum Essential Medium (αMEM) was used 
supplemented with 1% antibiotics and 1 – 10 % Dextran treated Charcoal 
stripped  fetal  bovine  serum  (DCC-  FBS)  to  minimize  artifacts  due  to 
different cell culture conditions. Unless not mentioned, cell lines were bought 
from ATCC or ETCC and used in maximum 10 passages from the original 
passage in our laboratory. All cell lines used in this thesis were routinely 
tested for mycoplasma. 
 
LNCaP FGC clone was originally derived from lymph node metastases and 
is androgen – dependent [259] and grows poorly in bone [260]. 
 
LNCaP-19 was established in our laboratory as an in vitro derived castration- 
resistant subclone of LNCaP [261]. LNCaP-19 has previously been shown to 
form osteoblastic tumors in the tibia of nude mice [262]and possess many of 
the  characteristics  of  human  CRPC.  Compared  to  its  parental  cell  line, 
LNCaP-19  grows  without  androgens,  has  an  increased  angiogenic  and 
invasive potential [263, 264]. It also forms metastases to lymph nodes and 
lungs when orthotopically implanted in SCID mice [265, 266] and 
occasionally to bone (unpublished). 
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C4-2B4 was originally derived from vertebral mouse metastases (kindly 
provided by Professor George Thalmann, Department of Urology, University 
of Bern, Switzerland). A second generation of LNCaP, C4 [267] was co- 
injected with a bone a stromal cell line, MS in mice to generate C4-2. The 
C4-2 was then cells were the injected orthotopically or subcutaneously back 
into castrated mice and formed  a bone metastatic subline, C4-2B4.    C4-2B4 
forms mixed osteoblastic/osteolytic tumors in mice [260]. 
 
The PC-3 cell-line is castration resistant and forms highly osteolytic lesions 
in bone (ref). It was originally isolated from a vertebral metastatic prostate 
tumor [268]. 
 
MC3T3-E1, clone 4, is a murine pre-osteoblastic cell line established and 
characterized by Wang et al [269]. The MC3T3-E1 is the most commonly 
used cell line for studies of osteoblast differentiation to be able to induce the 
complete differentiation process of a pre-osteoblast to a mature mineralizing 
mature osteoblast. 
 
NIH3T3  is  a  murine  fibroblast  cell  line,  and  was  used  as  a  control  to 
MC3T3-E1 in this thesis for valuation of osteoblast specific effects on the 
prostate cancer cells. 
 
Conditioned medium (Paper I-IV) 
The cross-talk between cells is mediated by either direct physical contact or 
released factors. Both forms of communication have shown to link several 
gene expression-directed signaling pathways. For the effect of osteoblasts on 
prostate cancer cells, communication via released factors appears to play a 
decisive role [84, 270]. Conditioned media was used in order to investigate 
bi-directional interplay between osteoblasts and tumor cells and the effect of 
secreted factors from either cell type. Abbreviations used in this thesis: 
prostate cancer cell-condition media (CM), fibroblast-conditioned media 
(FCM) and osteoblast-conditioned media (OCM). 
 
Differentiation assays 
The mineralization process in osteoblasts is well documented and can be 
studied  by  several  methods.  By  using  media  without  ascorbic  acid  it  is 
possible  to  maintain  the  cells  in  an  immature  stage,  and  by  adding 
promineralisation agents (β-glycerophosphate and ascorbic acid) 
differentiation can be induced.  In this thesis an ALP activity assay and the 
Von Kossa method were used for visualization of steps in osteoblast 
differentiation and finally mineralization (Paper I, IV) and OsteoImage™ 
Mineralization Assay (LONZA) was used for quantification of formed 
hydroxyapatite in osteoblasts (Paper IV). 
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Proliferation assay (Paper I-III) 
To study effects of treatment on proliferation of LNCaP-19 cells and MC3T3 
cells, we used the established method of BrdU-incorporation. BrdU is 
incorporated into the DNA of proliferating cells. It is an indicative method of 
proliferation. 
 
RNA and Protein preparations (Paper I-IV) 
RNA from cells were extracted by RNEASY mini plus kit (Qiagen) and RNA 
from femoral bone with ALLprep kit (Qiagen) according to manufacturer’s 
instructions. RNA concentrations were measured using a spectrophotometer 
(NanoDrop). Protein concentration was determined by the BCA Protein assay 
(Pierce Chemical) 
 
Real time - Quantitative Polymerase Chain Reaction (RT-qPCR) (Paper 
I-IV) cDNA was prepared by reverse transcription of total RNA with VILO 
Superscript III (Invitrogen) according to the manufacturer’s instructions. 
RTqPCR was performed with an ABI Prism 7500 Fast Sequence detector. 
Evaluation of mRNA expression was investigated using individual TaqMan 
MGB probes purchased as TaqMan Gene expression assays (Applied 
Biosystems).   For   characterization   and   comparative   analysis   of   basal 
properties and effects of osteoblast stimulation (OCM), human gene signature 
arrays  of  osteogenesis and androgen pathway were  used (Applied 
Biosystems; TaqMan® Array Gene Signature plates plates #4418741 and # 
4418728  respectively  )  with  96  selected  genes  including  4  endogenous 
control genes were used.  Genes were considered to be non-detected in cases 
where Ct values were above 36. 
 
Western blot (paper III) 
Samples were separated on a 4-12% Bis Tris gradient gel under reducing 
conditions and subsequently transferred to polyvinyldifluoride   PVDF 
membrane. Membranes were blocked in 2% blocking buffer followed by anti 
– RUNX2 and anti – CYP11A1. Beta actin was used as loading control. 
Protein expression was visualized using secondary anti-rabbit antibody and 
an ECL Advanced detection kit (GE Healthcare). 
 
RNA interference (Paper III) 
Transfection of LNCaP-19 cells was performed with Amaxa™ transfection 
cell   line   Nucleofector   kit™   (VCA-1001;   Lonza)   according   to   the 
manufacturer’s protocol. All siRNAs were purchased from Ambion, Silencer 
Select. Transfection efficacy was evaluated using 2 different siRNA and 2 
non targeting control siRNA and was confirmed by RT-qPCR and Western 
blot after 12, 48 and 72 h post transfection. 
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IN VIVO EXPERIMENTS 
 
Animal models 
Mouse models of prostate cancer are critical for understanding the biology of 
PC initiation, progression and therapeutic implications. As of yet, no model 
exists that can successfully reproduce the whole metastatic process and all of 
the environmental interactions that occur in the human disease. However, 
available models have been utilized in the study of different aspects of human 
prostate cancer bone metastasis and hence provide useful data. The injection 
of  tumor  cells  into  a  metastatic  site  (long  bone  such  as  femur,  tibiae, 
humerus) does not excludes the possibility to evaluate the factors associated 
with tumor cell migration, invasion and preferential homing to a particular 
metastatic site [271]. 
 
Limitations of this xenograft model is the lack of T-cells, and thus it does 
not mirror a full immune response. Nude Balb/c mice have B-cells and NK 
cells but the role of these in T-cell deficient mouse is not fully known. This is 
of special importance to consider for the results in paper IV. Like in humans, 
castration leads to decreased levels of steroids in mice and also results in 
bone loss. Also the main production of sex steroid in mice takes place in the 
testis and levels of sex steroids are drastically decreased after castration. 
However, there are also some major differences in sex steroid metabolism 
between humans and mice. In humans the adrenal gland is an important 
source of weak androgens that can be further converted to more potent 
androgens or estrogens. Rodents do not express adrenal CYP17A1, and thus 
the adrenal androgen production in mice is considered as insignificant, 
resulting in lack of circulating testosterone, DHEA and androstenedione 
synthesis [272]. Another difference is that mice lack SHGB, which is a high 
affinity carrier protein for sex steroids in serum in humans [273]. These 
points are of special importance to consider for the results in paper II. 
 
Animals and tumor cell implantations 
In this thesis male athymic BALB/c Nude mice were used for studies of the 
sclerotic growth of LNCaP-19 in bone. Intratibial implantations of LNCaP-19 
cells  were  used  to  study  the  osteoblastic  tumor  growth  locally  in  bone. 
Orthotopic and subcutaneous tumors of LNCaP-19 were used as controls for 
the bone specific effects. Castration was performed prior to implantation, via 
scrotal incision, to mimic the human condition of CRPC. Mice were 8-9 
weeks of age when the experiments started, this age corresponds to when 
mice turn sexually mature, which is an adequate start point for studies on 
prostate cancer. The use of the basement membrane product, Matrigel™ was 
used for all types of tumor cell injections. 
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Intratibial implantation Paper (I, II, IV) 
In the works of this thesis an intratibial injection model was used to study the 
interaction between tumor cells and bone microenvironment at the metastatic 
site. This method was established by Corey et al in 2004. In brief, tumor cells 
were   inoculated   directly   in   the   bone   marrow   via   the   knee   joint. 
Orthotopically and subcutaneus implantations were performed according to 
standardized methods (Paper II). 
 
The  use  of  animals  was  approved  by  the  animal  ethic  committee  in 
Gothenburg. 
 
Steroid measurements (Paper II) 
The most accurate method to measure sex hormones in mouse serum is the 
gas chromotography/tandem mass spectrometry (GS/MS-MS). This ultra- 
sensitive method [274] was used to measure steroids in tumor bearing mice in 
paper II. Serum concentration of progesterone, androstenedione, T, DHT, E2 
and estrone were measured in serum in a single run by GC-MS/MS. The 
limits of quantification for estradiol, estrone, T, DHT, progesterone and 
androstenedione were 0.5, 0.5, 8, 2.5, 74 and 12 pg/ml respectively. A 
limitation of this method is the amount of serum needed per sample- 250 µl. 
In Balb/c nude mice the maximum serum volume that can be obtained is 200 
– 250 µl per mouse, and therefore samples were pooled to be able to use 
serum for other analysis. 
 
Enzyme-linked immunosorbent assay (ELISA) (Paper I, II & IV) 
Markers of bone remodeling (OPG, RANKL) and osteoblast activity (OCN) 
were monitored in serum of mice to reflect the bone response of the tumor. 
Treatment effects of tasquinimod on pro- and anti-inflammatory mediators in 
serum were evaluated using a multiplex MCCYTOMAG- 70K assay (EMD, 
Millipore), based on magnetic bead technology to quantify 32 selected 
cytokines, chemokines and growth factors. The use of mouse-specific assays 
enables to study the tumor induced effect in bone. 
 
Immunohistochemistry (Paper II-IV) 
Immunohistochemistry   was   used   in   paper   II   for   identification   of 
steroidogenic enzymes and steroid receptors of intratibial, subcutaneous and 
orthotopic tumor tissue from LNCaP-19 xenografts and in paper III to verify 
RUNX2 and CYP11A1 localization and expression pattern in tumor cells and 
osteoblasts in intratibial sections. Antibodies for PSMA (prostate-specific 
membrane antigen) and P504s (alpha-methylacyl-CoA racemase) were used 
to distinguish the human tumor cells from mouse osteoblasts. In paper IV 
CD206, CD11b and Gr1 were used for detection of immune cells. To avoid 
false positives due to unspecific binding, a matched isotype control to the 
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antibodies was used in similar concentration. The choice of decalcification 
method is of importance for the performance of IHC. To minimize bias due 
to preparation of the tissue control staining was performed with both EDTA 
and formic acid treated bones. 
 
Biopix (Paper IV) 
In paper IV, the sclerotic effect of intratibially injected LNCaP-19 cells was 
abolished and hence there was no use to measure tumor response by BMD, 
Instead tumor mass was used as a parameter of tumor response in tibia of 
tasqunimod treated mice. For quantification of tumor area and number of Gr1 
and CD206 positive cells BioPix iQ 2.3.3 computerized color selection was 
used. 
 
Computed tomography (CT) (Paper I) 
To measure BMD, the peripheral quantitative computed tomography (pQCT) 
or can be used. The pQCT creates a 3D image of the bone and the true 
volumetric BMD and also separate the trabecular bone from the cortical 
bone. For trabecular bone analysis in mice, the sites investigated most often 
are of the proximal tibia, distal femur and vertebral body. In paper I, pQCT 
was used to calculate the sclerotic response of LNCaP-19 tumors in tibiae. 
Total and trabecular BMD were measured, ex vivo, in the metaphysis with the 
growth plate as a reference point. 
 
Statistics 
Statistical  differences  between  groups  were  established  using  two-sided 
Student's t-test (Paper I-IV). Mann-Whitney U test was used to analyze 
differences between groups in the in vivo experiments (Paper I, IV). 
Correlation was determined with Spearman’s rank correlation test (Paper 
I).Statistical calculations were performed using the latest version of SPSSv20 
software package (SPSS, Chicago, IL). A P-value of ≤ 0.05 was considered 
statistically significant. 
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RESULTS AND COMMENTS 
 
 
PAPER I 
 
Nearly all deaths from prostate cancer are the result of development of 
osteoblastic CRPC.  There is a lack of knowledge regarding the role of 
osteoblasts in the sclerotic process because of the limited amount of material 
from patients and a lack of experimental models that resemble the clinical 
characteristics of CRPC. To be able to further characterize the osteoblastic 
function in CRPC, new models are required. 
 
In this work, we characterized a new cell line model, referred to as LNCaP- 
19, that was previously established in our research group [261]. This model 
was used to study both basal mechanisms of sclerotic tumor growth of CRPC 
and the interplay between osteoblasts and tumor cells. In contrast to most 
bone metastasis models, the LNCaP-19 was derived in vitro and thus has not 
been in contact with stroma or bone, and this enables studies of the initial 
interactions and first contact with the bone microenvironment in vivo or with 
osteoblasts via soluble factors (such as OCM) in vitro. 
 
In order to grow and thrive in the bone microenvironment, tumor cells must 
be osteomimetic, i.e., they must have bone-like properties. To characterize 
the osteogenic properties of LNCaP-19, we used gene expression arrays to 
measure the basal expression of bone-associated genes and to identify genes 
that were affected by OCM stimulation. Expression analysis was performed 
on  androgen-dependent and castration-resistant cell lines that  were either 
bone-naïve or had been derived from bone. In accordance with the original 
study [19], we could show that prostate cancer cells express an inherent set of 
bone phenotypic genes, such as BMPs, VEGF, ALP, and the transcription 
factor genes MSX2 and RUNX2. During the transition to the castration- 
resistant stage, additional genes are expressed for a more pronounced 
phenotype. For instance, COL1A1 and DSPP, genes crucial for the 
mineralization process, were turned on during castration. The relevance of 
this gene expression could be demonstrated by the fact that the castration- 
resistant LNCaP-19 is able to induce mineralized matrix in vitro whereas 
androgen-dependent LNCaP lacked this capability. Interestingly osteolytic 
castration-resistant PC-3 cells did not have the capacity to mineralize in vitro, 
which could be explained by their expression of additional osteoclast 
phenotypic genes. 
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Koenemann suggested decades ago that the bone–stroma interactions are 
needed to fulfill the osteogenic phenotype in PC cells [19]. Our data support 
this theory and show that the stromal interactions with osteoblasts are likely 
the most important because fibroblasts do not induce bone-associated genes 
in CRPC cells. In accordance with observations by others, we could show 
that osteoblast-secreted factors stimulated proliferation [82, 84] and promoted 
the metastatic potential in osteogenic CRPC [275]. 
 
In addition, we could show that the osteoblast interaction further promoted 
the osteogenic progression in LNCaP-19 cells by increasing the expression of 
RUNX2 and CDH11 (osteoblast cadherin), which are suggested to be 
important for the bone tropism of prostate cancer [276, 277]. The interaction 
between tumor cells and bone cells is referred to as a vicious cycle and has 
been well characterized in osteolytic metastases from breast and lung cancer 
[278]. However, the vicious cycle of osteoblasts and prostate cancer cells in 
the sclerotic situation is poorly understood. Recently, MMP2 was shown to 
be of major importance in the vicious cycle of osteoblastic tumors [279]. The 
upregulated expression of CDH11 and MMP2 in the LNCaP-19 cells upon 
OCM stimulation suggests that OCM from osteoblasts potentiates the 
interaction between osteoblasts and prostate cancer cells by regulating these 
factors. 
 
The in vivo characterization of the intratibial LNCaP-19 model demonstrated 
that  our  model  had  many of  the  main  characteristics  of  human 
adenocarcinoma of the prostate in bone, i.e., osteodense bone without 
resorption and excessive osteoblast activity. Measurements by pQCT 
confirmed the osteoblastic response by a prominent increase in BMD in 
trabecular bone and in cortical bone. Serum markers of OPG, OCN, and 
RANKL (Paper II) were measured by ELISA and used as parameters for the 
osteoblastic tumor growth in this model. Osteoblasts control bone remodeling 
by secreting OPG or RANKL, and this axis has emerged as a key regulator of 
osteoclastogenesis in physiological and pathological states, including bone 
metastases  [280].  The  elevated  OPG/RANKL  in  serum  in  tumor-bearing 
mice indicates that local suppression of osteoclast activity might contribute to 
the overall osteoblastic response in CRPC tumors. 
 
Previous studies have reported that stimulation by CRPC cells leads to a 
significant increase in the population of immature osteoblasts [269, 281]. 
These findings are in agreement with clinical observations of CRPC 
metastases, which are composed of a large proportion of immature newly 
woven bone and non-mineralized matrix, that is also clinically reflected by 
increasing bALP levels in serum [197]. We demonstrated that osteogenic 
CRPC  cells  altered  the  differentiation  of  osteoblasts  as  evidenced  by 
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sustained ALP activity and the induction of a different mineralization pattern. 
We  also  demonstrate  that  BMD  in  tumor-bearing  mice  is  positively 
correlated with OCN levels in serum, which is a clinical marker for 
osteoblastic tumors in prostate cancer patients. To summarize, the LNCaP-19 
model resembles clinical CRPC thus making this model useful for studies of 
bone metastatic CRPC. 
 
In paper I, we present a novel model resembling bone metastatic CRPC. 
Furthermore we show that osteoblasts promote the metastatic and osteogenic 
progression of prostate cancer cells and the bi-directional interaction between 
tumor cells and osteoblasts. Our model demonstrates that both tumor cells 
and osteoblasts are mediators of the bone-forming process of CRPC, and this 
suggests that osteoblasts could be an important target for osteoblastic CRPC. 
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PAPER II 
 
As previously described, there seems to be a gradual shift during prostate 
cancer progression from dependence on androgens from endocrine sources to 
dependence of androgens from paracrine, autocrine, and intracrine sources 
[86]. Several studies on bone metastases from patients and from CRPC 
xenografts   have   demonstrated   increased   gene   expression   of   enzymes 
involved in the androgen synthesis pathway [60, 65, 87-89]. 
 
The potential of osteoblasts in regulating steroidogenesis was investigated in 
paper II. Using an androgen gene signature array, we show that osteoblasts 
alter the steroidogenic transcription program in CRPC cells, mimicking the 
gene expression pattern described in metastatic bone tissue from CRPC 
patients. Osteoblast-stimulated LNCaP-19 cells displayed an increased 
expression of genes encoding steroidogenic enzymes (CYP11A1, HSD3B1, 
and AKR1C3), estrogen signaling-related genes (CYP19A1 and ESR2), and 
genes for DHT-inactivating enzymes (UGT2B15, and UGT2B17). The altered 
expression pattern of steroid enzymes was bone specific and verified by 
immunohistochemistry   in   tissue   specimens   from   LNCaP-19   xenograft 
tumors. Measurements with a GC/MS-MS further supported both the 
steroidogenic gene expression analysis in vitro and the immunohistochemical 
staining ex vivo. The overall steroidogenic effect was reflected by 
corresponding levels of progesterone and a tendency for increased T and 
decreased DHT in serum from castrated mice with intratibial LNCaP-19 
tumors. 
 
Despite the sclerotic response of CRPC, there are currently no reports that 
link CRPC bone metastases and E2, but several studies show increased 
CYP19A1 [97, 98] – which is responsible for the conversion of T to E2 – and 
ERβ is reported to be increased in CRPC bone metastases  [282-284]. In 
addition, in the intratibial tumors of LNCaP-19, both progesterone receptor 
and ERα were expressed in osteoblasts and osteocytes. During androgen 
deprivation there was also an upregulation of ERβ in osteoblasts in vitro 
which suggest that there is a role for ER β in the sclerotic process of CRPC. 
In our model E2 levels were as expected not detectable in serum from the 
xenografts but in an additional study we could show that E2 is produced 
locally in bone harboring these tumors (unpublished data). Our studies show 
that osteoblasts have the capability to induce an intratumoral steroidogenic 
shift in favor of increased E2 production, which could explain the gain for the 
bone of hosting a CRPC.  During castration, bone degradation occurs due to 
decreased T and E2 levels, and because E2 is the main anabolic factor for 
bone, it is likely that increased synthesis of E2 in the CRPC tumor supports 
bone  formation  under  castrating  conditions.  In  contrast  to  our  data, 
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administration of E2 has been shown to have a direct inhibitory effect on 
tumor growth and prolonged survival in CRPC xenograft models [285]. 
However, these studies were based on subcutaneous tumors and cannot be 
directly translated to metastases in bone. 
 
It is likely that part of the heterogeneity regarding expression of steroidogenic 
enzymes reflects the AR status in the tumor cells. The mutated AR in the 
LNCaP-19 model might influence the observed steroidogenic pattern and 
thus might select for one subgroup. The T877A mutation has been found in 
up to 30% of clinical CRPC bone metastases [102, 286]. This point mutation, 
in accordance with nearby mutations in the ligand binding domain, leads to 
promiscuous binding to other androgen ligands such as E2 and progesterone. 
Due to the increased progesterone levels in the in vivo experiments, we 
performed an AR activity assay to investigate the responsiveness to 
progesterone in relation to DHT and T under castration conditions. We could 
show that progesterone activated mtT877-AR ten times more efficient than 
DHT, under castration conditions, thus suggesting that progesterone might 
have an important role in AR activation in these cells. Interestingly, the effect 
of osteoblasts was like in (Paper I) exclusively found in osteogenic CRPC 
cells and not seen in PC-3 cells, which are predominantly lytic in nature and 
do not express AR. Collectively, our study together with a previous study on 
clinical CRPC bone metastases, which showed that AR amplification 
correlated with decreased osteoclast activity [287], suggests that AR might be 
of importance for the osteoblastic phenotype of CRPC. In line with this, 
OCM increased the expression of transcripts for the glucuronoid enzymes 
UGT2B15 and UGT2B17. These enzymes have been found to be elevated 
after ADT, and are considered as the major androgen inactivation pathway in 
prostate cancer cells [288]. UGT2B15 and UGT2B17 are regulated by AR 
and are not expressed in PC-3 [289]. This might indicate that predominantly 
DHT inactivation (and possibly also T and E2) occurs in CRPC bone 
metastases. This can be interpreted in two different ways. DHT inactivation 
could be increased due to an overall increase of DHT within the tumor, or 
DHT inactivation could occur to limit the amounts of DHT. However, these 
alternatives were not the focus of this study. Together, the increased gene 
transcripts of theses enzymes could indicate that they are important for the 
osteoblastic response of CRPC. 
 
The unchanged levels of CYP17A1 in response to OCM might be related to 
the fact that CRPC cells expressing the T877A mutant AR are not dependent 
on CYP17A1 for their AR activation. Instead, AR activity in these cells is 
mediated by intratumoral pregnenolone/progesterone synthesis [95].  Another 
plausible explanation could be that CYP17A1 is activated by other stimuli 
than of osteoblasts. The latter is supported by the majority of studies on 
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human CRPC tumors where no increased CYP17A1 expression was detected 
in bone metastases [65, 87-89, 93]. However, blocking of CYP17A1 activity 
by abiraterone efficiently inhibits tumor progression in CRPC patients, 
resulting in a prolonged survival, and thus points out this enzyme to be 
important for the overall steroidogenesis in CRPC. In accordance with 
previous studies, on CRPC bone marrow biopsies [60, 95], we showed an 
increased expression of CYP11A1 in OCM stimulated LNCaP-19 cells.  In 
contrast, Jernberg et al did not detect CYP11A1 in the majority of bone 
metastases but identified a strong correlation between CYP11A1, CYP17A1, 
HSD3B2 and SRD5A1 in a subset of tumors [88]. This suggests that there are 
multiple ways for CRPC tumors in to produce steroids at levels adequate for 
sustained AR activity and maintained tumor growth. 
 
These findings provide further evidence that osteoblasts might be important 
therapeutic targets in osteoblastic PC because osteoblasts are important both 
for bone formation (Paper I) and steroidogenesis (Paper II) in osteoblastic 
prostate cancer. 
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PAPER III 
 
The gain of ectopic RUNX2 is suggested to be important in osteotropic 
cancers. However, little is known of the specific role of RUNX2 in 
osteoblastic tumors. The purpose of this study was to further characterize the 
acquisition of osteomimetic properties by CRPC cells and the role of RUNX2 
in the context of osteoblastic tumor growth. 
 
In Paper I, we identified the osteoblast transcription factor RUNX2 as one of 
the most up-regulated genes in osteogenic LNCaP-19 cells in response to 
osteoblast secreted factors (OCM). In contrast to the majority of studies on 
RUNX2 in prostate cancer (reviewed in [290]), we investigated the function 
of RUNX2 in a cell-line with osteoblastic properties, and we investigated the 
role of RUNX2 in the interplay between tumor cells and osteoblasts. 
 
Besides its pivotal role in regulating osteogenesis, RUNX2 was recently 
demonstrated to control de novo steroidogenesis in osteoblasts though the 
regulation of CYP11A1, the enzyme responsible for the conversion of 
cholesterol to pregnenolone [291]. In paper II, we found that CYP11A1 was 
upregulated by OCM, and we further hypothesized that the gain of RUNX2 
could be a mechanism in the acquisition of osteoblast-like properties as an 
adaptation for growing in bone. The purpose of this study was to address to 
what extent osteoblast-induced RUNX2 mediates the CYP11A1 expression 
and other osteoblast-induced phenotypes in LNCaP-19 cells. 
 
By silencing RUNX2 in LNCaP-19 cells, we could show that the osteoblast- 
induced expression of CYP11A1 was dependent on RUNX2, and thus we 
could show that osteogenic CRPC cells might utilize RUNX2 for de novo 
steroid synthesis in a similar manner as osteoblasts. In further verification of 
sclerotic tumors in LNCaP-19 xenografts, we could show that CYP11A1 and 
RUNX2  were  co-localized  at  the  borders  lining  the  tumor  island  and 
interlaced  within  the  newly  formed  bone.  CYP11A1  was  exclusively 
expressed in tumor cells, whereas RUNX2 was expressed in both osteoblasts 
and tumor cells, thus supporting the induction of RUNX2 in tumor cells by 
osteoblast-derived factors. In fact, RUNX2-expressing osteoblasts were 
difficult to distinguish from RUNX2-expressing tumor cells. Koeneman 
proposed in 1999 that the acquisition of RUNX2 might be a key event for the 
bone metastatic process of solid tumors [19], a further support for his theory 
has been provided by us and others [290, 292]. In addition, our observations 
also show that RUNX2 plays a novel role in osteoblastic metastases. 
 
Depending on its cellular expression level and context, RUNX2 appears to 
have   dual   roles   both   as   a   tumor   suppressor   and   as   an   oncogene. 
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Overexpression of RUNX2 has been shown to also drive osteolytic cancer 
aggressiveness and the osteolytic phenotype through the regulation of 
osteoclast stimulatory factors such as MMP-9, MMP-13, and IL-8 [292, 293]. 
In contrast to these reports, we found that these genes were upregulated by 
inhibition of RUNX2 by siRNA. In addition, OCM significantly abrogated 
the upregulation of IL-8. This would indicate that osteoblasts regulate part of 
the osteogenic phenotype of prostate cancer cells by controlling RUNX2 
expression. In support of our finding, it has been shown that inhibition of 
RUNX2 blocks the TGF-β–mediated stimulation of PTHrP, which is the most 
studied mechanism for the vicious cycle of osteolytic tumors [294, 295]. 
However, these experiments were mainly performed with cell lines such as 
the osteolytic AR-negative PC-3 cells, which do not represent the clinical 
phenotype of CRPC in bone. Other studies were performed using C4-2B, 
which, like PC-3, is derived from bone before being established in culture. 
This might influence the role and expression of RUNX2. However, RUNX2 
is known to be under the regulation of AR and ER (reviewed in [162]), and 
this regulation was not taken into consideration in paper III but might be of 
importance when considering our findings in a physiological context. 
 
In conclusion, paper III reveals a novel mechanism for RUNX2 in CRPC 
cells, which, under the regulation of osteoblasts, mediates de novo 
steroidogenesis and thus might be important for the intratumoral growth of 
CRPC in bone. 
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PAPER IV 
 
Tasquinimod (ABR-215050; a quinoline-3-carboxyamide) is small-molecule 
compound that has proven to have immune modulatory [296, 297], anti- 
angiogenic [298, 299], and anti-metastatic [262] properties in several 
experimental  tumor  models.  Recently,  a  randomized  placebo-controlled 
pivotal clinical study with tasquinimod showed reduced risk of radiographic 
cancer progression compared to placebo (rPFS, HR=0.69, 95% CI: 0.60-0.80) 
in patients with metastatic castration-resistant prostate cancer who had not 
received  chemotherapy.  However,  tasquinimod  did  not  extend  overall 
survival (HR=1.097, 95% CI: 0.938-1.282) [300]. In this pre-clinical study, 
we used the well-characterized LNCaP-19 model [301] to investigate the 
mechanisms of tasquinimod on osteoblastic growth of CRPC in castrated 
mice. 
 
In accordance with the previous pre-clinical studies [262], we found that 
tasquinimod inhibits tumor establishment and tumor growth in intratibial 
LNCaP-19 xenografts. In the treatment group, only a few mice developed 
tumors and these were very small and thus no pronounced osteoblastic 
response could be detected. These data support previous observations and 
show that tasquinimod interferes with the early phases in tumor establishment 
of osteoblastic bone metastases. 
 
Tasquinimod has previously shown inhibitory effects on the metastasis, 
probably  through its binding to the S100A9 protein, which has been shown 
to be an important factor in the creation of the pre-metastatic niche as well as 
in the recruitment and differentiation of MDSCs [302-304]. Within the niche, 
the bone is lined with osteoblasts expressing genes such as CDH11 and 
RUNX2  and  spindle-shaped  N-cadherin–positive  osteoblasts,  which  are 
special immature N-cadherin expressing osteoblasts (reviewed in [212]). In 
our study, the effect of tasquinimod on the niche was investigated in the 
tumor-free femoral bone marrow adjacent to the tumor cell-injected tibia. We 
found decreased expression of runx2, cdh2 (N-cadherin), and cdh11. This 
result implies that tasquinimod targets the osteoblastic component of the pre- 
metastatic niche, thus indicating new putative mechanisms for tasquinimod in 
CRPC in bone. 
 
A plausible mechanism for how tasquinimod inhibits the establishment of 
osteogenic prostate cancer cells could be by abrogating the expression of 
RUNX2, as seen in the femoral bone of tasquinimod-treated mice. RUNX2 
has proven to be important for the establishment of prostate cancer cells in 
the pre-metastatic niche where they attach to osteoblasts expressing RUNX2 
[221] . Moreover, RUNX2 is essential for bone development and osteoblast 
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maturation [305]. For example RUNX2-null mice die directly after birth due 
to the complete lack of differentiated osteoblasts and thus a lack of 
mineralized skeleton, which demonstrates the crucial role of RUNX2 in bone 
formation. The lack of sclerotic response might be directly coupled to the 
inhibition of RUNX2 because both OCN and col1a2 levels were decreased in 
the mouse femur, which are both under the regulation of RUNX2 [306, 307]. 
The inhibitory effect of tasquinimod on LNCaP-19-induced mineralization in 
osteoblasts  in  vitro  might  be  subsequent  to  the  phenotypic  switch  by 
decreased osteoblast markers, and this was supported by the elongated 
fibroblast-like phenotype shown in tasquinimod-treated osteoblasts in vitro. 
In addition, a plausible explanation for the mineralization effect could be the 
downregulation of lox, which is necessary for the final stages of the 
mineralization  process.  The  inhibitory  effect  on  tumor-induced 
mineralization in osteoblasts was also demonstrated in vitro by decreased 
hydroxyapatite formation. 
 
To evade an immune response, tumor cells directly modulate the immune 
system and induce an immune suppressive microenvironment by recruiting 
and activating immune-suppressive MDSCs and shifting the phenotype of 
tumor-infiltrating macrophages. We could show by immunohistochemistry 
that  tasquinimod  targeted  MDSCs  that  was  indicated  by  the  decreased 
number Gr1 positive and CD11b positive co-localized per tumor area in the 
treated intratibial tumors. In accordance with this decreased 
immunosuppression, we showed a phenotypic switch from M2 to M1 
macrophages in the femur adjacent to the tumor-injected tibia. The major 
evidence was the decreased expression of CD206 and Arg1 and increased 
expression of Nos2 (iNOS), which are markers of M2 and M1 macrophages, 
respectively, in mice [234, 308, 309]. In addition, it has been shown that 
inhibition of RUNX2 blocks the TGF-β–mediated stimulation of PTHrP, 
which is the most studied mechanism for the vicious cycle of osteolytic 
tumors. Interestingly, TGF-β leads to the expansion, activation, and 
recruitment of MDSCs [226]. In line with the observation in paper III, it is 
tempting to suggest that suppressed TGFβ and the subsequent abrogation of 
MDSCs might be a cause of repressed Runx2. 
 
In conclusion, paper IV shows that tasquinimod efficiently impaired the 
establishment of bone metastases in mice by interfering with the osteoblastic 
pre-metastatic niche and osteoblastic activity, thus emphasizing the role of 
osteoblasts in the early phases of the metastatic process of CRPC. 
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GENERAL DISCUSSION 
 
Models of prostate cancer bone metastases 
Multiple animal models of prostate cancer bone metastasis have been 
developed, but only a few effectively resemble osteoblastic bone metastases 
as they occur in men. Prostate cancer only arises spontaneously in men, dogs 
and more rarely in rodents. Therefore the use of xenograft models, in which 
human tumor cells are administrated into mice provides the opportunity to 
study human prostate cancer in a physiological context and allows for 
assessment of the interaction between tumor cells and the bone 
microenvironment in the metastatic process. 
 
A major problem with the existing xenograft models of prostate cancer is that 
they, for unknown reasons rarely form metastases. Intravascular injections 
via the tail vein is used as a model of extravasation and metastasis, and 
intracardiac injection of cancer cells into the left ventricle permits cancer 
cells to localize to any tissue of the body depending on the cancer cells’ 
inherent metastatic phenotype. However, these injection models can be 
controversial as metastasis models, because they eliminate the early steps of 
metastasis and thus fail to fully recapitulate human disease. 
 
Intratibial implantations were first used to investigate the growth properties 
of different prostate cancer cell lines in bone [310]. The intratibial injection 
of tumor cells into a metastatic site (a long bone such as the femur or tibia) 
does not preclude the possibility to evaluate factors associated with tumor 
cell migration, invasion and preferential homing to a particular metastatic site 
[271]. Because femurs are larger than tibiae they can be used as a semi 
metastatic model [311]. Even though intratibial injections do not resemble 
the natural course of metastasis, we were able to use such a model to study 
steps such as modulation of/and attachment to the osteoblastic niche and 
tumor establishment using both the tumor injected tibia and the femoral bone 
(Paper IV). 
 
The available prostate cancer cell lines that predominantly form osteoblastic 
tumors in bone are patient-derived bone marrow metastases (VCaP  and 
LAPC-9) or are established by being co-injected with stromal cells in bone of 
mice before being established as cell lines from xenografts (C4-2B4) [312- 
314]. In both cases the stromal cell contribution and the adaptation to bone 
can influence the overall tumor response. Several CRPC cell lines have been 
developed in vitro by culturing the cells in steroid-deficient media for several 
passages as in the case of LNCaP-19 [261]. However few of them form 
osteoblastic tumors in vivo. An advantage of using in vitro derived cell lines 
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is that these cell lines are bone-naïve and thus are suitable for studies of the 
initial   osteoblast   –   tumor   cell   interaction   and   the   basal   mechanism 
contributing to the establishment of CRPC in bone. In addition, some 
osteoblastic models do not have the capacity to grow or to form mixed 
osteoblastic/osteolytic tumors in the absence of androgens, and thus these 
models do not resemble clinical CRPC. Another challenge regarding the 
available osteoblastic prostate cancer models is their inability to propagate in 
vitro, which makes them unsuitable for use in in vitro assays to investigate 
the molecular mechanisms of pathogenesis in parallel with in vivo studies. 
Our model mimics the situation of osteoblastic CRPC both in vitro and in 
vivo, and thus making it a valuable tool for studies, both at the molecular 
level and under physiological situations in mice. 
 
The heterogeneity in prostate cancer bone metastases is a major problem with 
regard to the development of resistance, and this heterogeneity can result in 
poor  treatment  response  in  some  metastatic  phenotypes  when  directed 
therapy  is  used  [122,  197,  315].  In  the  clinic,  PSA  is  used  to  monitor 
treatment  effects  and  the  progression  of  bone  metastasis.  Our  model 
expresses low PSA levels, and does not respond to osteoblast-derived factors 
(OCM) with increased PSA expression in vitro. In a similar study, OCM has 
been shown to induce PSA secretion in prostate cancer cells [84]. Even if a 
high PSA value (> 100 ng/mL) is indicative of metastatic disease, it is 
probably more correlated to a high tumor burden rather than high PSA 
expression in the metastatic cells per se. Studies on  patients with low PSA 
levels (< 10 ng/dl) [316], still identified bone metastases in a significant 
portion of patients. Thus, PSA levels alone cannot be used as a marker of 
bone metastases. Interestingly, patients with both primary tumors and bone 
metastases expressing high levels of PSA have been  convincingly  shown  to 
have a better prognosis compared to patients with tumors expressing low 
levels of PSA [122, 315, 317, 318].  PSA expression is heterogeneous and the 
absence or low expression of PSA cannot be explained solely by populations 
of AR-negative neuroendocrine cells or stem cells, which are rarely seen in 
bone  metastases  [122,  319,  320].  Furthermore,  there  is  no  correlation 
between PSA and AR expression in human CRPC bone metastases [315]. 
Altogether, this might indicate that the expression of PSA could reflect some 
degree of tumor cell differentiation, dedifferentiation or transdifferentiation 
that can occurs under influence of the bone microenvironment. 
 
Subgroups of CRPC bone metastases – including splice variants, mutations, 
or the loss of AR – can also be characterized by AR status together with 
different steroidogenic patterns. Models like LNCaP-19, which harbors a 
mutated AR, might be relevant to the 10–30% of patients with CRPC who 
harbor this mutation [286]. Plausible explanations for the different growth 
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properties in bone observed in papers I and II, could be that there were 
differences in the osteomimetic properties of the cell lines and the origin of 
cell type, as well as AR status and the steroidogenic capability to adapt to the 
bone microenvironment under castration condition. Therefore characterizing 
major tumor subgroups and elucidating the underlying mechanism of the 
growth pattern in bone might lead to the development of therapeutic 
approaches targeting tumor cells in some cases and bone cells in others. 
 
Osteolytic versus osteoblastic tumors 
Although it is clear that the involvement of different interactions between the 
tumor and the bone microenvironment, the “vicious cycle”, driving the 
metastatic progress in bone metastases is far more complex than originally 
proposed. In general, osteoblastic tumors are described as slow growing 
tumors while osteolytic tumors are characterized to be more aggressive and 
fast growing. What drives the different tumor response of CRPC in this 
aspect is not known. In our study we show that osteoblasts influence sclerotic 
tumor progression in many steps of the metastatic process of CRPC (Paper I- 
IV).  The respective phenotypes of dysregulate bone destruction and bone 
formation represent two ends of a spectrum, and most patients will have 
evidence of both processes to some extent. However, during disease 
progression one phenotype will be dominating and for patients with prostate 
cancer the vast majority will end up with a sclerotic phenotype. Even though 
this pattern is characteristic for prostate cancer, disease progression alone 
cannot explain the osteoblastic dominance in end- stage CRPC and the 
osteolytic dominance in late-stage breast cancer patients because a proportion 
of CRPC patients will develop osteolytic disease while a similar proportion 
of breast cancer patients will develop osteoblastic disease. The mechanisms 
responsible for tumor growth in bone are complex and involve tumor 
stimulation of osteoclasts and osteoblasts as well as the response of the bone 
microenvironment. Osteoblasts are implicated in the regulation of bone 
homeostasis and bone remodelling through the secretion of factors that will 
either stimulate or suppress osteoclast activity, thus suggest that osteoblasts 
might provide a regulatory mechanism of cytokines in the bone 
microenvironment [129, 237].  However, among experimental models the 
osteolytic  phenotype  tends  to  predominate,  as  exemplified  by  the  AR- 
negative PC-3 cell line, indicating that the mechanism behind CRPC 
acquisition might in part also influence bone-related properties of the 
metastases.   Our studies have shown that osteoblasts do not stimulate 
osteolytic CRPC cells (Paper I and II), and we and others have shown that 
osteogenic and osteolytic cell lines display different profiles regarding 
cytokines and osteoclast stimulatory factors [321-323]. This suggests that 
these different phenotypes should be treated as different forms of the disease. 
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The role of RUNX2 in osteolytic versus osteoblastic prostate cancer 
The work in this thesis suggests that RUNX2 is involved in CRPC cell 
adaptation to the bone microenvironment by inducing genes related to both 
osteomimicry and steroidogenesis (Paper I, II and III). As evidence for the 
role of RUNX2 in the phenotypic fate of prostate cancer bone metastases, 
RUNX2 appear to behave differently in AR positive versus AR negative 
tumors of CRPC. In different types of tumor cells, RUNX2 cooperates with 
its co-activators or co-inhibitors to mediate the response of cells to various 
signaling pathways that are hyperactive in tumors [290]. Relevant for prostate 
cancer, are the AR and ERα pathways. RUNX2 directly binds to the AR and 
this interaction is potentially important for androgen signaling in various 
contexts including bone metabolism and prostate cancer progression [324, 
325]. This regulation has not been addressed in our studies but it is important 
for understanding the complexity and function of RUNX2 in CRPC. 
 
RUNX2 has been extensively studied in the context of osteoblastogenesis and 
bone development where it directs mesenchymal stem cells to the osteoblast 
lineage. Ectopic expression of RUNX2 is increased in breast cancer and 
prostate cancer cells that metastasize to bone, indicating pro-tumorigenic and 
pro-metastatic roles [290]. In prostate cancer the expression of RUNX2 
positively  correlates  with  Gleason  score  [292,  326,  327].  RUNX2  is 
suggested to be a key regulator of events associated with the metastatic 
progression of prostate cancer to the bone – and possibly contributing to their 
metastatic potential, in part by stimulating the expression of matrix 
metalloproteases such as MMP9 and MMP13 [328, 329] and by promoting 
EMT, tumor cell survival and invasion into bone tissue [292, 295, 330, 331]. 
In paper I, RUNX2 expression was shown to be increased by osteoblast- 
derived factors in osteoblastic CRPC cells while levels of RUNX2 in 
osteolytic CRPC cells were unchanged. This could indicate that osteoblasts 
regulate RUNX2 in CRPC bone metastasis and are a part of the osteoblastic 
vicious cycle. In our study, expression of RUNX2 was found in both tumor 
cells and osteoblasts in intratibial tumors of LNCaP-19 (Paper III) supporting 
a bidirectional role of RUNX2 in the sclerotic CRPC. In support of our 
hypothesis,  short  hairpin-mediated  inhibition  of  RUNX2  in  pre-clinical 
models suppresses the metastatic growth in bone of osteolytic prostate cancer 
(PC-3)  and  breast  cancer  with  high  expression  of  RUNX2  [292].  This 
indicates the importance of RUNX2 for the growth of osteotropic tumors in 
bone. However, the role of RUNX2 in bone metastatic CRPC needs to be 
further investigated pre-clinically and its clinical importance needs to be 
confirmed in bone metastatic tissue from patients. 
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The   different   roles   of   RUNX2   in   tumorigenesis   and   the   divergent 
development of osteolytic and osteoblastic tumors might be explained by the 
different roles of osteoblasts in these situations. Based on clinical and pre- 
clinical data including the data presented in this thesis, it appears that a 
population of immature RUNX2 expressing osteoblasts and the stimulation 
of ectopic expression in the tumor cells are important for the osteoblastic 
growth of CRPC. We have shown that RUNX2 is induced in tumor cells 
close to osteoblasts in the intratibial tumor model in mice. In addition, both 
breast and prostate cancer cells preferentially home to RUNX2 expressing 
osteoblast  in  the  niche  [221].  In  contrast,  osteoblasts  do  not  stimulate 
RUNX2 expression in osteolytic tumor cells (PC-3) that have high RUNX2 
expression. Interestingly, silencing RUNX2 has been shown to promote an 
osteoblastic phenotype, thus indicating that expression levels of ectopic 
RUNX2 are important for the different phenotypes. Together this suggests 
that  osteoblasts  play  an  important  role  in  the  regulation  of  the  tumor 
phenotype through the expression of RUNX2. In addition, our data suggest 
that RUNX2 is important for homing to a niche and in the communication 
between tumor cells and osteoblasts within the niche. 
 
For patients with CRPC a plausible therapeutic option could be to modulate 
RUNX2 with combined treatment for bone remodeling to maintain bone 
homeostasis. As indicated by our data (Papers I-III) targeting RUNX2 could 
be an effective strategy for targeting both osteoblasts and ectopically RUNX2 
expressing osteoblast-like tumor cells. From a therapeutic point of view, 
RUNX2  could  be  an  ideal  target  because  CRPC  patients  have  an  adult 
skeleton and do not have the acute need to form new bone. Thus combining a 
RUNX2 modulator with currently used drugs such as denosumab and 
zoledronic acid might be a feasible treatment alternative. 
 
ADT and prostate cancer bone metastasis 
The optimal time point for ADT treatment is still a matter of debate. ADT 
remains the single most effective treatment of metastatic prostate cancer, but 
it is uniformly marked by progression to CRPC. The vast majority of patients 
who receive ADT have already developed lesions in the bone. Although the 
initial response to ADT is a decreased tumor mass in the prostate tumor and 
in distant lesions as well as a decrease in the metastatic spread of the cancer 
cells, ADT commonly gives rise to osteoporosis that leads to the release of 
tumor cell-stimulating growth factors. An increased number of tumor cells 
both in the prostate and in the circulation (DTCs) might be available for 
adaption to the castration conditions, and events such as osteomimicry might 
be  promoted.  Therefore,  removing  the  prostate  before  ADT  could  be  a 
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strategy  to  prevent  or  prolong  the  time  to  development  of  castration 
resistance. 
 
It is important to identify prostate cancer subtypes and the proper timing for 
ADT depending on the type of tumor that we aim to treat. In some cases 
castration might actually trigger the metastatic process in bone, while in other 
cases it might inhibit metastasis.  In our in vivo model, we could not detect 
AR in any of the bone cells while AR expression in the tumor cells interlaced 
within the bone was prominent and had a nuclear localization, thus indicating 
that AR is important for the sclerotic tumor growth of CRPC. A report by 
Efstathiou et al [252], showed that the anti-androgen enzalutamide had 
significant therapeutic effect in patients with CRPC bone metastases who had 
strong AR expression before treatment. The effect of enzalutamide in these 
tumors was shown by subcellular translocation of the AR out of the nucleus 
and  subsequently  inhibition  of  AR  signaling.  However,  a  subgroup  of 
patients (37%) who had the AR-V7 AR splice variant exhibited enzalutamide 
resistance. 
 
Administration of an aromatase inhibitor in older men with low T  levels 
increases T but decreases E2 levels and BMD, and this suggests that the 
increase in T cannot compensate for  the negative effect  of E2 deficiency on 
the skeleton [332]. In contrast, selective estrogen receptor modulators have 
proven effective in treating bone loss with ADT in prostate cancer patients 
[333]. In recent trials, monotherapy with anti-androgens such as bicalutamide 
and enzalutamide that prevent AR activation instead of reducing the synthesis 
of androgens did not show a significant effect on BMD [334]. The fact that 
peripheral aromatase activity might modulate circulating E2 levels is of 
particular   interest   because   most   estrogens   in   men   are   derived   from 
conversion of androgens in peripheral tissue [335, 336].  Moreover, estrogen 
deficiency have a profound effect on the immune system leading to increased 
production of proinflammatory cytokines like IL-1, TNF-α, INF-γ, IL-6 and 
IL-17, both systemically and in bone marrow,  and this might contribute to 
increased bone resorption [337]. 
 
To evaluate the clinical relevance of our model pQCT measurements of BMD 
were assessed to determine the bone- formation capacity of LNCaP-19 cells 
(Paper I). Interestingly, tumor-induced trabecular BMD was significantly 
elevated in castrated mice compared to non-castrated mice. Accordingly, in a 
recent experiment from our group, intratibially implanted LNCaP cells had 
the capacity to increase trabecular BMD in castrated mice but to a lesser 
extent than LNCaP-19 (unpublished data).  In contrast, the commonly used 
C4-2 forms mixed osteoblastic/osteolytic tumors and leads to an overall 
decrease in BMD under castration conditions [338]. These data suggest that 
Malin Hagberg Thulin 
57 
 
 
 
castration influences the osteoblastic tumor response of CRPC. In paper II we 
demonstrated a low expression of AR in osteoblasts in tumor-bearing bone 
tissue  and  this  could  be  an  indication  that  a  prominent  population  of 
immature osteoblasts is present in these tumors (Paper I-IV). In fact, AR 
expression in osteoblasts is known to increase along with maturation with the 
highest expression in the mineralizing phase [298]. This could indicate that 
immature osteoblasts in the pre-metastatic niche, which are characterized 
with RUNX2 expression, might not be severely affected by castration, and 
this might explain how metastasis can proceed during ADT and might even 
lead to a survival advantage for the pre-metastatic niche. In accordance with 
the osteomimetic changes in tumor cells that occur during the transition into a 
castration-resistant form, this indicates that castration/ADT might trigger the 
bone metastatic process of CRPC.  How ADT affects the overall osteoblastic 
tumor growth of CRPC needs to be investigated further. 
 
Intratumoral steroidogenesis in osteoblastic CRPC 
Enzymes involved in steroidogenesis have been shown to be upregulated in 
clinical CRPC tissue and in mice under castrate conditions [60, 65, 87-89]. 
and the increased steroidogenic potential of tumor cells has been suggested to 
contribute to the development of castration-adapted tumors within the 
metastatic site. Due to the fact that both prostate cancer cells in general and 
bone are dependent on sex steroids for their growth and maintenance of bone 
mass, we suggest there is a mutual interplay in the tumor microenvironment 
that is regulated, at least in part, by osteoblasts.  We propose that osteoblasts 
facilitate  the  intratumoral  steroidogenesis  needed  for  sclerotic  growth.  In 
paper II, we could show that osteoblasts induced most of the enzymes 
described in human bone metastatic CRPC tissue (Figure 5). 
 
We also demonstrated for the first time serum levels reflecting the changes in 
intratumoral steroidogenic enzymes on the mRNA level in CRPC bone 
metastases in vivo.  In line with our study, Knuttilla et al confirmed steroid 
levels in serum to corresponding increases in mRNA in an orthoptoic VCaP 
model  [339], thus  strengthening the  relevance  of  the  mRNA data  in the 
present study. However, in contrast to the intratibial model in our study, most 
changes in hormonal levels were reflected in response to castration and not to 
the tumor. These data suggest that intratumoral steroidogenesis occur in 
sclerotic tumors of CRPC, and this supports the many studies, both clinical 
and preclinical, that report of increased mRNA levels of steroidogenic 
enzymes.  The clinical relevance of these enzymatic changes and subsequent 
intratumoral steroidogenesis in bone metastatic CRPC, is demonstrated by 
the response to abiraterone, a CYP17A1 inhibitor, in many CRPC patients. 
Despite   improvements   targeting   the   AR-axis   (enzalutamide)   and   the 
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enzymatic steps in steroidogenesis (abiraterone), resistance inevitably 
develops and remains the major obstacle for long-term survival. This again 
emphasizes the need for new treatment targets, in which the osteoblastic 
stimulation of osteomimicry and intratumoral steroidogenesis could be one 
possibility target. 
 
 
 
Figure 5. Osteoblast-induced regulation of steroidogenesis in a model of osteoblastic CRPC. 
The arrow indicates the enzymatic steps in the androgen synthesis pathway that exhibit 
increased  versus  decreased gene  expression  in  LNCaP-19  cells  in  osteoblast-conditioned 
media (OCM). Green arrows = increased expression, white arrows = unchanged expression, 
and red arrows = decreased expression. Data are based on mRNA and levels of steroids in 
serum from in vitro culture and intratibial xenografts of osteoblastic CRPC. 
 
It is well known that E2 is the main anabolic factor for bone and its 
formation. Also a marked up-regulation of CYP19A1, which mediates 
the aromatization of testosterone to E2, has been observed in human 
CRPC bone metastases compared to primary tissue [60, 97]. Despite 
this, E2 and progesterone are seldom mentioned in CRPC, and the 
intratumoral and serum ratio of steroid levels are uniformly reported as 
the T/DHT ratio. The sclerotic response CRPC resembles the effect of 
E2 in bone. In accordance we could show (paper II) that OCM 
significantly increased the  expression  of  CYP19A1 in  vitro  and  in 
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intratibial tumors in LNCaP-19 xenografts. In an unpublished 
experiment by us, local steroid levels in tumor-bearing tibiae were 
measured in castrated mice, and showed detectable levels of   E2, 
progesterone, DHT and T. This is the first study, to our knowledge, 
that actually has detected E2 levels in castrated male mice. In line with 
this, we could show corresponding expression of protein of ERα, ERβ, 
and the E2 regulated- progesterone receptor in the intratibial tumors 
(Paper II). Although the role of ERβ in human bone biology is not well 
understood,  the  fact  that  is  expressed  in  the  majority  of  bone 
metastases [282-284], strongly indicate that E2 signaling have a role in 
CRPC in bone. ERβ expression was detected in tumor cells while both 
ERα and the progesterone receptor were expressed by osteoblasts 
(Paper II). This is in accordance with several studies that have shown 
increased expression of ERβ in bone metastatic tissue whereas ERα 
has been undetected  (reviewed in [340]). Interestingly, mRNA of ERα 
was  expressed  solely  in  the  CRPC  cell  lines  in  vitro  and  not  in 
androgen dependent LNCaP (Paper II). Hence suggest that ERα might 
be of importance for the transition into a castrated form while ERβ 
might be important for the growth of CRPC in bone. 
 
In our study (Paper II), the increased progesterone levels in the serum of 
tumor-bearing mice support the importance of progesterone for the 
osteoblastic response of CRPC in mice. Despite conflicting reports on the 
effect of progesterone on osteoblasts,   with some studies suggesting an 
anabolic action and others showing no effect, the expression of   progesterone 
receptor   in   osteoblasts   plays   a   physical   role   [341].   The   increased 
progesterone levels in response to LNCaP-19 cells in tibia (Paper II) could 
indicate that progesterone might be of importance for the total the sclerotic 
growth of CRPC, mediated by osteoblasts, while a sustained synthesis of 
androgens might be more crucial for the tumor cells. However, the 
steroidogenesis is complex machinery and the physiological importance of 
certain metabolites for the progression of CRPC need to be further 
investigated. 
 
The heterogeneity in prostate cancer probably influences the responsiveness 
to treatment. A growing body of evidence shows that tumors in clinical 
CRPC and in pre-clinical material, tumors can be divided into subgroups with 
a distinguished expression pattern of steroidogenic enzymes. More recently it 
appears  that  specific  features  of  AR  correlate  with  these  patterns.  For 
example CYP11A1 and the de novo steroid synthesis pathway are mostly 
studied in the LNCaP sublines that harbor a mutated AR, and increased 
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expression of AKR1C3 and SRD5A1 is coincident with naturally occurring 
AR splice variants [88]. As we showed in paper II, osteoblasts induce 
steroidogenic changes in certain CRPC cells. It is thus plausible that only a 
modest increase in either key enzyme in the steroidogenic pathway together 
with  the  adrenal  derived  androgen  precursors  or  cholesterol  might  be 
adequate to drive AR activity and tumor growth in CRPC. 
 
Thus, it is reasonable that depending on the bone microenvironment and the 
origin of the tumor initiating cell, these changes results in tumor subgroups 
that  have  survival  advantages  in the local environment.  ADT  selects for 
certain subtypes of tumor cells that are capable to maintain steroid synthesis 
locally. Defining subgroups based on their steroid enzyme pattern and AR 
status might prove useful as a prognostic biomarker and also for guidance in 
the development of novel therapeutic strategies or patients with CRPC bone 
metastases. 
 
Therapeutic approaches for osteoblastic metastasis of CRPC 
Currently approved therapies against CRPC bone metastases are focused to 
target the tumor cells and do not fully consider the contribution of the host. 
One remaining question to address is why prostate cancer in a unique way 
induces osteoblastic metastases. Our studies have shown that osteoblasts are 
vital in several key mechanism of CRPC bone metastasis (Paper I-IV). In 
paper I, we showed that osteoblasts promote the osteogenic and metastatic 
progression of CRPC, which might explain part of the proclivity of prostate 
cancer cells to metastasize to bone. Despite their emerging role in the 
metastatic progression, few attempts have been made to specifically block 
osteoblast activity. One of the promising osteoblast targets investigated in 
preclinical and clinical trials has been ET-1. ET-1 is a vasoconstrictive agent 
that stimulates osteoblast proliferation and enhances osteoblast differentiation 
[145, 342]. Strong support for its ability to target prostate cancer skeletal 
metastases in animal models has led to investigation in human clinical trials. 
Atrasentan was the first ET-1 antagonist to be investigated in patients with 
prostate cancer, and currently, zibotentan, a promising more selective ET-1 
inhibitor  is  in  clinical  trials  [343].  It  has  also  become  clear  that  that 
interaction between tumor cells and the bone microenvironment is an early 
event in the metastatic process as the primary tumor prepares the niche 
metastatic site by releasing soluble factors such as VEGF, IL-6 and CCL2 
[324], but when and how this event occurs is far from understood. In paper 
IV, we could show that by interfering with the osteoblastic pre-metastatic 
niche, the drug candidate tasquinimod inhibited tumor establishment and 
tumor growth possibly by interfering with the pre-metastatic niche, thus 
indicating the importance of osteoblasts for homing and the establishment of 
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metastasis of prostate cancer. However, the niche also serves as a reservoir 
for dormant tumor cells that can resist chemotherapeutic attack, and these 
tumor cells can emerge later as new metastases in bone or other organs [206, 
256, 344]. It is suggested that dormant DTCs might start the process in the 
niche. In the bone marrow, cancer cells are often resistant to chemotherapy 
because they are held in the G0 phase of the cell cycle through contact with 
bone marrow stromal cells. Because these cells are considered to be resistant 
to radiotherapy and chemotherapy, a beneficial strategy could be to remove 
the prostate even in patients who are initially diagnosed with established 
bone metastases. In general the prostate is not currently surgically removed 
or  locally  treated  in  men  with  clinically  evidenced  bone  metastases  [3]. 
Taking into consideration of the paracrine signaling between the prostate and 
osteoblasts (niche) in bone, both before and after establishment in the bone, 
our study would suggest that by removing the prostate, it could be beneficial 
for patients with osteoblastic CRPC. 
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CONCLUSIONS 
 
The main observations and conclusions of the present investigations can be 
summarized as follows. 
 
• The established LNCaP-19 model resembles human sclerotic CRPC, 
sharing many pathological and molecular characteristics, and thus 
provides opportunities for in vitro and in vivo studies of the 
osteoblastic tumor progression of CRPC. 
 
• The osteomimetic properties of CRPC cells might be inherent and 
some are increased during castration. 
 
• Osteoblasts    further    promote    the    osteogenic    and    metastatic 
progression of osteogenic CRPC through the stimulation of genes 
associated with bone – such as RUNX2 – and they stimulate the 
expression  of  CDH11  and MMP2  in  CRPC  cells, which  enables 
cross talk with osteoblasts. 
 
• Osteoblasts  induce  and  alter  steroidogenesis  in  osteogenic  CRPC 
towards increased progesterone, T, and E2. This bi-directional 
interplay allows for the growth of tumor cells and de novo bone 
formation, which might in turn explain part of the castration-resistant 
growth of CRPC in bone. 
 
• Osteoblasts  might  regulate  de  novo  steroid  synthesis  in  CRPC 
through RUNX2-dependent CYP11A1 activation. This suggests that 
RUNX2 is a key factor in the sclerotic growth of CRPC and 
osteoblasts and might be a good target for inhibition of 
steroidogenesis. 
 
• Targeting the osteoblastic niche has a profound inhibitory effect on 
both  the  establishment  and  growth  of  CRPC  in  bone,  and  this 
suggests that osteoblasts are a strong candidate for therapeutic 
intervention. 
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